3rd annual sachs cancer bio partnering & investment forum

SUPPORTING ORGANISATIONSORGANISERS

PRESENTING COMPANIES

WELCOM

ESPEAKERS

3rd Annual

Sachs Cancer Bio Partnering &

Investment Forum Promoting Public & Private Sector,

Collaboration & Investment in Drug Development

www.sachsforum.com

23rd February 2015New York Academy of Sciences • USA

Conference Guide

3RD

AN

NU

AL

SA

CH

S C

AN

CER

BIO

PA

RTN

ERIN

G &

IN

VES

TMEN

T FO

RU

M



WELCOM

ESPEAKERS

3rd ANNUAL

Cancer Bio Partnering & Investment Forum

3rd AnnualCancer Bio Partnering & Investment Forum

t back :: next u

Request for PresentationsPlease use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

Sachs Associates are delighted to welcome you to the:

General Information• The registration desk is open from 8.00am on 23rd February although you are welcome to

join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

• One-to-one meetings Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.

Sachs Associates, building upon it’s many years of expertise in organizing premier

partnering and investor meetings in Europe and the United States, is proud to

welcome you to the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum being held on 23rd February 2015 at the New York Academy of Sciences. This forum is designed to bring together thought leaders from cancer

research institutes, patient advocacy groups, pharma and biotech to facilitate

partnering and funding/investment.

Sachs Associates would like to thank our sponsors and partners who have helped

make this event possible.

3rd Annual

Sachs Cancer Bio Partnering & Investment ForumPromoting Public & Private Sector,Collaboration & Investment in Drug Development 23rd February 2015 • New York Academy of Sciences • USA



WELCOM

ESPEAKERS

3rd ANNUAL



t back :: next u

Events Diary

For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Silvia Kar on [email protected]

8th Annual European Life Science CEO Forum & ExhibitionPartnering & Investing in Biotech & Pharma Industry03rd – 04th March 2015 • Hilton Zurich Airport Hotel • SwitzerlandBack for its eighth year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships.

Building on the success of this year’s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.

The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives!

Event details available at: www.sachsforum.com/zurich_elsceo15

Sachs Immuno-Oncology: BD&L and Investment Forum 29th May 2015 • Chicago • USA

15th AnnualBiotech in Europe Forum For Global Partnering & Investment29th – 30th September 2015 • Congress Center Basel • SwitzerlandThe forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s bio industry, this event will once again be covered by our regular media partners. We expect over 600 delegates and 100 presenting companies.

The 15th Annual is again being held in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The Programme will feature plenary panels/workshops covering BD & Licensing in the main therapeutic areas. There will be significant networking opportunities at the Forum and receptions.

Event details available at: www.sachsforum.com/basel15

3rd AnnualMedtech & Diagnostics Innovations Summit16th November 2015 • Düsseldorf • GermanyThe Summit is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be covered.

The program will also feature public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech and Device companies track will cover; Oncology, Cardiovascular, Imaging, Surgical Devices & Implants, with a separate track for Diagnostics.

View last year’s event at: www.sachsforum.com/mdis14



WELCOM

ESPEAKERS

Speakers

3rd ANNUAL



t back :: next u

Barrett J. Rollins MD, PhD, Linde Family Professor of Medicine, Harvard Medical SchoolChief Scientific Officer, Dana-Farber Cancer Institute

Dr. Rollins received his undergraduate degree from Amherst College, and his MD and PhD from Case Western Reserve University. He completed internship and residency training in Internal Medicine at Beth Israel Hospital, Boston, and a fellowship in Medical Oncology at Dana-Farber Cancer Institute. Dr. Rollins has been a member of the faculty at Dana-Farber since 1989. His research examines the effects of inflammation on cancer with a recent emphasis on the genetic alterations associated with childhood histiocytic diseases. As Chief Scientific Officer at Dana-Farber, Dr. Rollins has helped lead a project designed to obtain broad genomic profiles on all patients who come to the Institute for cancer care. Dr. Rollins is the Linde Family Professor at Harvard Medical School, a member of the American Society for Clinical Investigation, a member of the Association of American Physicians, and a Fellow of the American Association for the Advancement of Science.

Bernhard Sixt, President and CEO, ImmunID

Dr Sixt has over 25 years of pharmaceutical industry experience in the development and commercialization of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare), and Nycomed (now part of Takeda). He is a co-founder of Agendia and has served as the company’s CEO from 2003 until 2011. Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University, and a PhD from the Technical University, both in Munich, Germany.

Anne Altmeyer, VP, Business Development, Head Negotiation, Oncology, Novartis Pharmaceuticals

Anne Altmeyer is Vice President, Head Global Negotiations in Business Development & Licensing (BD&L) in the Oncology Business Unit at Novartis. In this capacity, her responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. She also oversees the group responsible for Companion Diagnostics transactions and manages several ongoing alliances.

Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and BD&L. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. There, she led numerous multidisciplinary Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager in various Therapeutic Areas at Merck & Co.

Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a MBA and a MPH from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.

Beth Jacobs, Managing Partner, Excellentia Global Partners

Founder and Managing Partner of Excellentia Global Partners, a life science focused investment bank based in New York. Prior to founding EGP, Beth served in senior executive positions at Morgan Stanley, Lehman Brothers, ING Barings and Furman Selz where she founded and led the International groups. She serves on the Boards of the Harvard Kennedy School of Government, Women’s Leadership Board, the New York Academy of Sciences Executive Committee, and other cultural not for profit institutions.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Claudio Carini, Global Head of Immunology & Biomarkers, Pfizer

Claudio Carini leads biomedical research in the area of inflammation and personalized medicine. Studied Medicine in Italy and trained in internal medicine and clinical immunology. Completed PhD in Immunology at the University College London (UCL), London. Completed membership of the Royal College of Pathologists, London and Specialist Diplomas in Clinical Immunology and Respiratory Medicine, School of Medicine, Rome.

Presently, Claudio is the Global Head Clinical Immunology and Biomarkers at Pfizer and a Hon. Faculty at King’s College, School of Medicine, London. Held faculty positions at Harvard, Johns Hopkins, UCL, Rome and senior roles at Wyeth, Novartis, and Roche.

He is also presently serving in national and international scientific boards: F-NIH Biomarkers Consortium “Inflammation & Immunology” Steering Committee; F-NIH Biomarkers Consortium “RA Working Group” Steering Committee; F-NIH Biomarkers Consortium “SLE Working Group” Steering Committee; F-NIH Biomarkers Consortium “Ankylosing Spond.Working Group” Steering Committee; MRC, (UK “Inflammation/ Immunology Initiative – UK RA Consortium, Steering Committee; MRC, (UK) “Stratified Medicine, SLE Consortium, Steering Committee; Biomarkers Development Center, Amsterdam, NL, Advisory Board; IMI, ABIRISK, European Union/EFPIA” Board of Directors and The PML Consortium, Board of Directors

His research interests include understanding the role of biomarkers and precision medicine in autoimmune diseases.

Claudio is published widely in areas of immunology and molecular medicine. Over 200 publications in national and international peer reviewed journals.

Claudio chaired a conference on “Companion Diagnostics: From Biomarkers Identification to Market Entry” New York Academy of Science, 2014

He co-edited two books in the field of Personalized Medicine: “Biomarkers in Drug Development: A handbook of practice, application and strategy”, John Wiley, 2010 and “Clinical and Statistical Considerations in Personalized Medicine”, CRC, 2014

Claudio is a member of various national and international societies.

Catherine Pickering, Head of Oncology Licensing, Global BD, EMD Merck Serono

Catherine is the Head of Global Licensing & Business Development Oncology & Immuno-Oncology at Merck Serono. In this role, she leads a team of business development professionals involved in all aspects of deal making for Merck Serono’s oncology business. The team has been responsible for several key pipeline deals including the co-development /co-commercialisation deal with Threshold, the licensing deal with Symphogen and more recently the PDL1 deal with Pfizer. Prior to this role, Catherine spent several years in the business development and alliance management organisation at Antisoma (a UK Biotech company) covering both search and evaluation as well as transaction execution in oncology and managing their key strategic alliance with Roche. Before her industrial business development career, Catherine worked in the technology transfer team at the Institute of Cancer Research in London where she was responsible for spinning out several biotechs and creating multi asset research collaborations with pharma and biotech.

Catherine grew up in London and holds a Ph.D. in medicinal chemistry from The Institute of Cancer Research (a college of the University of London) and an MBA from Henley Management College.

Daniel Auclair, Vice President, Translational Research, Multiple Myeloma Reseach Foundation, Inc.

Prior to rejoining the MMRF in 2013, for whom he had managed the Multiple Myeloma Genomics Initiative from 2007-2010, Dr. Daniel Auclair worked at the Broad Institute of MIT and Harvard as a senior leader in the Cancer Program, where he was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine.

Prior to this, he spent a decade in the pharmaceutical industry, most notably at Bayer Healthcare, where he led a number of cancer drug discovery efforts. Dr. Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Dennis J. Purcell, Senior Managing Partner, Aisling Capital LLC

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association and the Irvington Institute. He also serves on the Board of L.E.K. Consulting.

Mr. Purcell received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.

Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance

Mr Mitteldorf is a leading international patient advocate, with over 18 years of global experience in men’s cancer advocacy. Mr. Mitteldorf is also an inventor, with patents in radiotherapy and other areas. He is also the founder of the worlds first cancer research crowdfunding platform, startacure.org His particular expertise is indeveloping public private partnerships.

Dov Hass, Associate, Morgan, Lewis & Bockius LLP

Dov Hass is an associate in Morgan Lewis’s Business and Finance Practice. Mr. Hass’s practice focuses on venture capital financings, acquisitions, divestitures and mergers, joint ventures and strategic partnerships, and providing general corporate and securities representation to emerging growth and life science companies.

As a significant part of his practice, Mr. Hass represents pharmaceutical and biotechnology companies in transactions such as the negotiation and structuring of strategic alliances and other collaborations, licensing transactions, supply and distribution arrangements, co-promotion arrangements, and joint ventures. He also advises companies from a broad range of industries on general corporate and transactional matters.

Mr. Hass earned his J.D. from Fordham University School of Law in 2005. Prior to attending law school, he was a conference director for the Institute for International Research’s biopharmaceutical division, where he produced conferences for the pharmaceutical and biotechnology industries. Mr. Hass also served as a healthcare investment banking analyst in the private placement group of Ladenburg Thalmann, where he focused on the biotechnology industry.

Daniel Teper, CEO, Immune Pharmaceuticals Inc.

Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. Dr. Teper was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Monitor Group). Daniel started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, where he help launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Dragan Cicic, COO, Actinium Pharmaceuticals, Inc.

Dragan Cicic is the COO and CMO of Actinium Pharmaceuticals, Inc. (ATNM). He joined the company in 2005 and previously held the position of the Medical Director with Actinium Pharmaceuticals, Inc. Dr. Cicic joined ATNM from the position of Project Director of QED Technologies Inc., a life sciences strategic consulting and transactional group focused on emerging biotech, pharmaceuticals and medical devices companies. Dr. Cicic prepared business and strategic plans on behalf of those clients and assisted them in raising funding. He also represented corporate and private investors in identifying acquisition and/or investment targets and negotiating, structuring and consummating deals.

Dr. Cicic graduated as a Medical Doctor from the School of Medicine at The Belgrade University, and received his M.B.A. from Wharton School at The University of Pennsylvania. He was also a Nieman Fellow at Harvard University.

Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo Inc.

Dr. Kern is currently Senior Director of External Scientific Affairs at Daiichi Sankyo where he is responsible for identifying and evaluating in-licensing, partnering, and external research collaboration opportunities in Oncology.

In his previous position as Scientific Officer and Head of Program Development for Oncology at the Adelson Medical Research Foundation, he developed a portfolio of collaborative and interactive translational research programs in ovarian cancer, melanoma, lymphoma and lung cancer involving key opinion leaders at major academic research and Cancer Centers throughout the U.S., Europe, Australia and Israel. Prior to that, as Senior Director of Oncology at Lexicon Genetics, he implemented novel approaches to oncology drug target identification and validation and was charged with advancing targeted anticancer therapeutics.

The academic portion of his career primarily involved establishing and directing a basic and translational research program on molecular and cellular mechanisms underlying breast cancer progression to antiestrogen-resistant and metastatic phenotypes. He began this program first as a Senior Staff Fellow in the Breast Cancer Section of the Medicine Branch of the National Cancer Institute and subsequently as a faculty member at the Lombardi Cancer at Georgetown University and as Director and Department Head of Biochemistry and Molecular Biology at the Southern Research Institute in Birmingham, Alabama where he also held the Adolph Weil Endowed Chair in Cancer Biology. While there, he also had program and executive oversight leadership roles within the University of Alabama at Birmingham’s NIH-Designated Comprehensive Cancer Center as co-leader of their Women’s Cancer Program. He also has a history of extensive service on federal basic science or small business oncology-related grant review panels.

He received his bachelor’s degree in Biological Sciences from Rutgers College and his Ph.D. in Microbiology from Rutgers University and his postdoctoral training in Cellular and Molecular Biology at the NYU Medical Center.

Gil Beyen, Chairman and CEO, Erytech Pharma

Before joining ERYTECH, first as Chairman, than as Chairman and CEO in 2012. Gil was the co-founder and CEO of TiGenix (NYSE Euronext: TIG BB) for 12 years. Before that, he was the head of the Life Sciences division of the Arthur D. Little consultancy company in Brussels. He received an MS degree in Bioengineering from the University of Louvain (Belgium) and an MBA from the University of Chicago (USA).



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer

Dr. Naeve is currently the Rinat Lead and Head of Pfizer’s External R&D efforts for the Cancer Immunotherapy program. He is also head of global scouting in the Northwest region of North America. In this role Greg is responsible for liaising with Pfizer Scientists to identify and institute strategic partnerships that address internal technology and pipeline needs. Prior to Pfizer he worked as a venture capitalist with the San Francisco-based life science venture fund, The Column Group, a firm focused on creating biotechnology companies to develop novel therapeutics and technologies. Prior to that he was the President and Chief Scientific Officer of Parallax Biosystems, a company he co-founded to develop a molecular detection platform with applications in pre-clinical drug discovery and diagnostics. Before Parallax he held positions at Neurocrine Biosciences and Amgen working to develop new therapies for neurodegenerative disorders. He received his Ph.D. in Biochemistry from the University of Southern California.

Howard J. Fingert, Senior Medical Director, Business Development & Clinical Intelligence, Takeda Oncology

Howard Fingert, M.D, is Senior Medical Director for Clinical Intelligence and Business Development in the Dept of Internal and External Innovation for Takeda Oncology. He was formerly the Therapeutic Area Head for Oncology in the Dept of Medical and Scientific Analyses at Pfizer. With over 20 years biotech/pharma industry experience in Clinical Development, Regulatory Affairs, and Business Development, Howard’s responsibilities have spanned diverse academic and Industry partnerships, supporting multiple successful product registrations in Oncology, Immunotherapy, and other indications. Board certified in Oncology and Hematology, his prior faculty positions were at Harvard and Tufts medical schools with published experience in phases 1-3 clinical trials, pharmacology, and clinical risk management. He also serves as the current Industry Representative to the FDA Oncology Drugs Advisory Committee (ODAC), providing guidance to multiple Industry sponsors seeking marketing authorization for drugs or biologic products.

Jeff Abbey, President & CEO, Argos Therapeutics, Inc.

Jeffrey D. Abbey has served as President and Chief Executive Officer of Argos Therapeutics and a member of the board of directors since February 2010. Mr. Abbey served in various other positions at Argos from September 2002 to February 2010, including as Vice President of Business Development from February 2004 to January 2009 and as Chief Business Officer from January 2009 to February 2010. Prior to joining Argos Therapeutics, Mr. Abbey served as Vice President of Business Development and Finance at Internet Appliance Network, an information technology company, from 1999 to 2001. Mr. Abbey was a partner at Eilenberg and Krause, LLP, a corporate law firm, from 1994 to 1999. Mr. Abbey received an A.B. in mathematical economics from Brown University and an M.B.A. and J.D. from the University of Virginia.

Jens Eckstein, President, S.R.One Limited

Dr. Eckstein comes to SR One from TVM Capital where he was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He is currently Chairman of the Board of Directors of Thrasos Therapeutics and a Director at Alios BioSciences. He also was a member of the Board of Directors for CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an Advisor to Sirtris Pharmaceuticals.

Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, Jens led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc.

He is the author of multiple scientific publications and holds several issued and pending patents. Jens is an Advisor to the Alzheimer Research Forum (ARF), a Board Member of BioHealth Innovation (BHI) and a Kauffman Fellow.

Jens is the father of three teenagers and lives with his family in Dover, Massachusetts.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Ji Li, Vice President, Business Development and Licensing, Merck & Co., Inc.

Dr. Ji Li joined Merck in 2013 as VP BD&L and Head of Late stage Assessment. In this position, Dr. Li is overseeing Merck’s global effort in the assessment of all late stage partnering opportunities across all TAs. Prior to joining Merck, Dr. Li held the position of Executive Director, External R&D at Amgen where he was leading the company’s search and evaluation function for all product-related business development transactions worldwide. Prior to his business development career, Dr. Li was a discovery scientist at Amgen in the area of bone, inflammatory and metabolic diseases. Dr. Li holds a B.S. from Shanghai Medical University in China and Ph.D. from Mount Sinai School of Medicine in NYC.

Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche

Juan Carlos López was born in Oaxaca, México, in 1967. He obtained his first degree on Biomedical Research at the Universidad Nacional Autónoma de México, majoring in neuroscience. Juan Carlos got his Ph.D. degree from Columbia University (New York) in the laboratory of Eric Kandel, studying synaptic plasticity in neuronal cultures. He then carried out postdoctoral work at the Instituto Cajal (Madrid), studying presynaptic mechanisms of transmitter release. During this period, Juan Carlos wrote a book on the neurobiology of memory (“El Telar de la Memoria”, Algar Editorial), with which he won the IV European Award of Scientific Dissemination in 1998. Two years later, Juan Carlos left experimental research to become Editor of Nature Reviews Neuroscience in London. In January 2004, he returned to New York to become the Chief Editor of Nature Medicine.

In February 2014, Juan Carlos left the publishing industry to become Head of Academic Relations and Collaborations at Hoffmann-La Roche. In this role, he and his team are charged with fostering interactions of his company with academic institutions worldwide with the aim of promoting the advance of translational research and the discovery of new medicines.

Juan Carlos has also served as a member of the Scientific Advisory Board and of the Board of Directors of Noscira, a Spanish biotechnology company interested in neurodegeneration. He is member of the Board of Directors of the Eureka Institute, an international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in bridging the gap between bench and bedside, and of the Board of Directors of Keystone Symposia, non-profit organization devoted to the advancement of science through its prestigious series of conferences.

Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society

Lee has over 25 years experience in Oncology Research and Development.

Since September 2013, Lee has been Chief Scientific Officer of the Leukemia and Lymphoma Society. His responsibilities focus on planning and executing the strategy for all LLS research programs, including a grant portfolio with 320 active projects, the Therapy Acceleration Program (TAP) with over 15 opportunities, as well as other research initiatives. Dr. Greenberger guides LLS’s efforts to translate innovative research into clinical trials that ultimately will pave the way for new therapies to treat blood cancers. The total annual budget for these activities is approximately $75 M.

Immediately prior to LLS, Dr. Greenberger was global head of search and diligence for oncology and immunology at Bristol-Myers Squibb where he examined opportunities for over 200 oncology companies and helped set the business strategy for oncology and immunology. Prior to that, he served for six years as vice president for research at Enzon Pharmaceuticals where he was responsible for pre-clinical pharmacology, toxicology, process development, and analytical chemistry efforts associated with the discovery and development of oncology assets. Prior to Enzon, Lee held positions of increasing responsibility in the research organizations of Johnson & Johnson and Wyeth Pharmaceuticals, where he began his industry career in 1990 at American Cyanamid/Lederle Laboratories, which was later acquired by Wyeth. He was given the President’s Award for his work at Wyeth.

Dr. Greenberger holds a bachelor’s degree from the University of Rochester and a Ph.D. from Emory University. He has done post-doctoral work at Columbia University and was on faculty at the Albert Einstein College of Medicine. Dr. Greenberger has produced more than 85 publications, mostly focused on oncology, during his research career.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Lisa Ricciardi, SVP Corporate & Business Development, Foundation Medicine

Lisa Ricciardi joined Foundation Medicine in July 2014 with a broad range of experience in global and specialty pharmaceutical commercial operations, pharmacy benefits, management, and healthcare services. She has successfully collaborated with an extensive network of industry leaders in the United States, Europe and Japan, and she has played a key role at the board and executive levels on strategic transactions and product launches.

Ms. Ricciardi previously served as a consultant to the specialty pharmacy division of Davita RX, a full-service pharmacy specializing in renal care. Prior to this role, was senior vice president of US and international business development at Medco Health Solutions, Inc., and was a venture partner at Essex Woodlands Health Ventures. She a held numerous senior management positions at Pfizer, including senior vice president in the licensing and development division, closing more than 25 transactions with multinational firms and biotechnology companies, as well as managing several key product launches in the global pharmaceuticals division.

She is currently a member of the Board of Directors of United Drug Group, PLC in Dublin, Ireland, and a director with Chimerix in Durham, North Carolina; in addition, Lisa was previously a member of the Board of Directors at Sepracor. Ms. Ricciardi earned an MBA from the University of Chicago and a bachelor’s degree with honors from Wesleyan University.

Leigh Zawel, Site Head, New York and Boston Centers for Therapeutic Innovation, Pfizer

Dr. Leigh Zawel joined Pfizer in 2013 to lead CTI’s work in the Boston office. In 2014, in addition to being the site head in Boston, Dr. Zawel became site head to CTI’s New York office. Before CTI, Dr. Zawel was the oncology site lead at Merck Research Laboratories (MRL) Boston. In this role, he was responsible for drug discovery efforts focused on the identification of development candidates for programs in the oncology franchise. Dr. Zawel worked previously at Sanofi-Aventis, where he was Director of Cancer Biology, and Novartis Institutes for Biomedical Research/Oncology, where he was an Oncology Group Leader. Dr. Zawel has a deep background in identifying and validating oncology drug targets and in transitioning drug discovery programs through lead optimization to Phase 1 clinical trials.

Dr. Zawel earned his Ph.D. in the laboratory of Danny Reinberg where he identified and characterized components of the RNA Polymerase II basal transcription machinery. Dr. Zawel’s postdoctoral training was in the laboratory of Bert Vogelstein and Ken Kinzler and focused on dysregulation of TGFB signaling in cancer. Dr. Zawel also holds a MS in Bacteriology from the University of Wisconsin, as well as a BS in Biology from Rutgers University. He has published more than 30 scientific publications. He is also an author on 45 patents covering chemical matter, drug combinations, biomarker utility and gene function in areas of apoptosis, inflammation and TGFB signaling.

Louise M. Perkins, Chief Science Officer, Melanoma Research Alliance

Dr. Perkins joined the Melanoma Research Alliance (MRA) as Chief Science Officer in 2013 where she is responsible for the development and implementation of the MRA’s scientific strategy to eliminate suffering and death due to melanoma. Her interests center on translational research including genomics, drug discovery and advancement of novel therapeutic approaches. Prior to joining the MRA, she was Chief Scientific Officer at the Multiple Myeloma Research Foundation (MMRF) for five years following a research career of 16 years at two major pharmaceutical companies.

While at the MMRF, Dr. Perkins led the continued expansion of its venture philanthropy investments including its Biotech Investment Award and Clinical Fund programs. In addition, she was responsible for the expansion of the MMRF’s Genomics Initiative which sequenced the first myeloma tumor genome in 2009 and has comprehensively analyzed 250 myeloma patient samples with an array of genomic technologies including next-gen sequencing. More recently, Dr. Perkins led the development of the genomics and data sharing strategy underpinning the MMRF’s 1,000 patient longitudinal study, CoMMpasssm, which aims to develop new targets and biomarkers through deep clinical and molecular data capture and analysis.

Prior to joining the MMRF, Dr. Perkins was Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar® and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a cancer research group at the Schering-Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Marc Mansour, CEO, Immunovaccine Inc.

Marc Mansour holds a Ph.D. in biology and has completed a Master of Business Administration. He is an expert in vaccinology and cancer immunotherapy. Since he joined Immunovaccine, Dr. Mansour led the clinical development of the DepoVax™ platform and the Company’s lead therapeutic cancer vaccine DPX-Survivac, soon entering randomized Phase II trials in ovarian cancer and glioblastoma. He represents the company to the investor and scientific communities. He continues to lead the internal development of vaccines based on the DepoVax™ platform, and externally with collaborators and commercial partners.

Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald

Mara Goldstein is a managing director, head of healthcare research and senior analyst covering the biotechnology sector with Cantor Fitzgerald. Ms.Goldstein’s career in equity research spans a broad continuum of life sciences subsectors, including biotechnology, major pharmaceuticals, drug delivery and specialty pharmaceuticals. Prior to joining Cantor Fitzgerald, Ms. Goldstein was most recently with Thomson Reuters, where she served as director of research Reuters Insight, an independent research services business. Ms. Goldstein was initially responsible for the firm’s healthcare research practice, and later assumed responsibility for all research activities and sectors. Prior to that, Ms. Goldstein was an executive director and senior pharmaceutical analyst at CIBC World Markets, and she also worked at Alex Brown & Sons (now Deutsche Bank) and CS First Boston (now CSFB). Ms. Goldstein has been quoted in publications such as The Wall Street Journal, New York Times and Newsweek, and has appeared on financial television news programs such as CNBC, Bloomberg TV and ABC World News. She holds a bachelor’s degree in economics from Purdue University.

Maxim Jacobs, Senior Healthcare Analyst, Edison Group

Maxim joins Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years’ experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.

Mike Rice, Senior Consultant, Defined Health

Since joining Defined Health in 2005, Mike has participated on project teams and managed projects pertaining to cardiovascular disease, oncology and a variety of other therapeutic areas, as well as those focused on complex therapeutics such as protein and gene‐based therapies for monogenetic diseases.

Mike brings to Defined Health over 10 years of experience as a biotech entrepreneur. Most recently, as Strategic Business Development Analyst for Tapestry Pharmaceuticals, Mike combined technical knowledge and business analytics to evaluate early stage development pipelines for partnering and licensing efforts. He was previously involved in translational research and technology transfer as Project Leader in Genomics at the Delaware Biotechnology Institute. Mike gained exposure to the venture capital community as a technological founder and New Product Development Manager of the genomics and gene therapy firm, Kimeragen, Inc.

Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to cancer genetics, DNA repair, human gene therapy, molecular diagnostics, and agricultural trait improvement.

Mike holds an MBA, New Venture Creation, Biotechnology Degree from the Alfred Lerner School of Business and Economics, an MS in Molecular Pharmacology from Thomas Jefferson University and a BS in Biology from the University of Delaware.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



O. Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute

O. Prem Das, PhD, is Chief Research Business Development Officer at Dana-Farber Cancer Institute (DFCI) and heads DFCI’s Office of Research and Technology Ventures (ORTV). ORTV is responsible for patenting and licensing discoveries made by DFCI researchers to outside company to create income. ORTV also works with DFCI faculty and Integrative Research Centers to enhance relationships with the corporate sector, generating sponsored research agreements and collaboration opportunities in both clinical and preclinical research. Prem’s background includes around eight years of experience in managing academic technology transfer offices, twelve years in biotechnology business development, and fifteen years in basic research. Prior to joining DFCI in 2012, Prem was involved in starting up companies and consulting for biotechnology companies and the NCI. From 2006 to 2007, he served as Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development efforts led to the acquisition of the company by Glaxo SmithKline. Prem directed the Office of Technology Licensing at Harvard Medical School from 2003 to 20006 and the Office of Industrial Affairs at Memorial Sloan-Kettering Cancer Center from 2000 to 2003. He co-founded Heartland BioTechnologies and was Director of Business Development at Cadus Pharmaceuticals in the ‘90’s. During his academic research career, Prem has published in diverse areas of biology and chemistry. He received his MSc in chemistry from IIT/Kanpur in India and his PhD in biological chemistry from MIT.

Paul Higham, Managing Director, immatics biotechnologies GmbH

Paul Higham was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland.

Prior to joining Ark Therapeutics in 2001, Paul Higham worked from 1996 to 2001 as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc, where he was responsible for all aspects of international commercial strategy. From 1985 to 1996 he held various sales and marketing positions of increasing responsibility with Bayer AG becoming General Manager of Bayer Pharmaceuticals for Sweden and Denmark. He has a degree in Applied Biology.

Peshwa Madhusudan, Executive Vice President, Cellular Therapies, MaxCyte, Inc.

Madhusudan Peshwa, Ph.D., currently serves as Executive Vice President, Cellular Therapies at MaxCyte, Inc. Most recently, he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company. Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals’ production. Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Philippe Mauberna, CFO, Nanobotix

Philippe has joined Nanobiotix as CFO in June 2013 to conduct the company’s international growth within the Executive Board.

Before joining Nanobiotix, Philippe has been heavily involved in financial projects with an international exposure during start-up launch or innovative SME development. Dedicated to the Life Sciences industry for more than 10 years, he has hold Financial and Operations senior positions to reinforce EMAE commercial effectiveness for Astellas Pharma. As consultant, he has provided change management support for European pharmaceutical companies during their commercial development phase.

Philippe holds a degree in Finances from Paris Assas University, followed by a Management course at INSEAD.

Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center

Peter Hoang is the Senior Vice President, Business Development & Strategy at Bellicum Pharmaceuticals, where he is head of business development, corporate development and business strategy. He has over 18 years of finance and deal experience in investment banking and venture capital. Prior to Bellicum, he was the Managing Director, Innovations for The University of Texas MD Anderson Cancer Center and headed the institution’s new venture formation and development effort. Prior to MD Anderson, he was a senior investment banker, most recently as Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group. Previously, he also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch and Deutsche Bank. He earned high honors distinction with an M.B.A. from the Anderson School of Management at UCLA and a B.A. from Yale University.

Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis SA

Dr. Raffaele Baffa is an experienced pharmaceutical executive and an academic and clinical physician, who has been involved in all stages of biomedical research – from bench experimentation to clinical research – for over 20 years.

Dr. Baffa is currently the Head of Translational Sciences, ESI, Global Biotherapeutics, at Sanofi in Cambridge, MA, USA. Prior to his position as Head of Translational Sciences, ESI, he was responsible for developing and implementing strategic translational and clinical plans for early stage compounds as a Senior Director of Translational and Experimental Medicine for the Oncology Business Unit at Sanofi.

Dr. Baffa has been the author or co-author of 90 papers, mainly in highly refereed journal (Cell, NEJM, Jama, PNAS, Cancer Research, etc.), and has authored 14 book chapters. He was a Kimmel Scholar (Sidney Kimmel Foundation) in 2001. He is also member of numerous national and international societies, and serves on editorial boards of scientific journals.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Robert de Petit, Chief Scientific Officer, Advaxis

Dr. Robert Petit has over 25 years of experience in all medical and scientific aspects of pharmaceutical development. A co-founder of the Immunotherapy Program at St. Lukes Medical Center and former Assistant Professor of Pathology and Laboratory Medicine at the University of Wisconsin Medical College, he Joined Industry in the 90s. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV for dozens of products and personally contributed to 5 NDA/BL filings and the launch of 3 major drugs in Immunology and Oncology. Dr. Petit joins Advaxis from Bristol-Myers Squibb where he was the U.S. Medical Lead for the Yervoy (ipilimumab) program, director of Medical Strategy for New Oncology Products and director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as vice president of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Dr. Petit has a Doctorate from the Ohio State University College of Medicine in Immunology and Medical Microbiology and a B.S. from Indiana State University.

Robert O. Dillman, Vice-President of Oncology, NeoStem, Inc.

Dr. Robert O. Dillman, served as CSC’s Chief Medical Officer prior to the CSC Acquisition, and now holds the title of NeoStem’s Vice President, Oncology.

Dr. Dillman has served as the Executive Medical Director of the Hoag Hospital Institute for Research and Education, in Newport Beach, California, a position he has held since 2011. Prior to this position he served as Executive Medical Director of the Hoag Family Cancer Institute from 2008-2011, and was Medical Director of the Hoag Cancer Center from 1989-2008. He has also served as a Clinical Professor of Medicine at the University of California, Irvine (“UCI”) since 1989. Dr. Dillman chaired the Cancer Biotherapy Research Group from 1990 to 2002, and is a past President and board Member of the International Society for Immunotherapy of Cancer.

Dr. Dillman has directed a cell biology research laboratory focused on patient-specific cell therapies for more than 20 years. He is an internationally recognized leader in cancer immunotherapy approaches, including monoclonal antibodies, adoptive cell therapies, IL-2, and cancer vaccines. He has authored more than 300 medical publications and is recognized internationally for his work in lung cancer, lymphoma, Chronic Lymphocytic Leukemia (CLL), melanoma, and kidney cancers. He was the first physician in Orange County, California to be selected as one of the Best Doctors in America in Hematology and/or Oncology. In 2006, Dr. Dillman was named Orange County Physician of the Year by the Orange County Medical Association. In 2008, he received Hoag Hospital’s first endowed chair, the Grace E. Hoag Endowed Chair of Oncology and in 2010, he became one of only five recipients in the world to receive the Distinguished Service Award from the Society for Immunotherapy of Cancer.

Dr. Dillman received his undergraduate degree from Stanford University and medical degree from Baylor College of Medicine. He also completed both his internship and residency in Internal Medicine at Baylor College of Medicine, and served as a Chief Resident. He completed his fellowship in Hematology/Oncology at University of California, San Diego Medical Center.

Rowan Chapman, Managing Director, Ventures, GE Healthcare

Rowan is focused on creating new businesses and investing in digital health, data analytics and precision medicine. Prior to joining the GE Ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content. Before GE, Rowan spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Rowan invested in and held board director and observer roles across a spectrum of healthcare and life science companies, including Adamas (ADMS), Balance Therapeutics, HealthTap, RainDance, Pacific Biosciences (PACB), ParAllele (AFFX), Personalis, Sequenta and Verinata (ILMN). Prior to joining Mohr Davidow Ventures, Rowan was very early employee at Rosetta Inpharmatics (IPO’d then acquired by MRK) and a Product Marketing Manager at Incyte Genomics. She holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a postdoctoral fellow at the University of California, San Francisco.



WELCOM

ESPEAKERS

t back :: next u

Speakers

3rd ANNUAL



Stephen Brozak, Managing Partner and President, WBB Securities, LLC

Steve Brozak is President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors. Mr. Brozak is an award winning analyst whose research has been singled out from his peers for accuracy and performance year after year by the financial industry’s most highly regarded rankings organizations. His research is currently monitored by the StarMine and FactSet platforms. Mr. Brozak has written articles and opinions for Businessweek-Bloomberg, Forbes, CNN, ABC News, and The British Medical Journal on trends in the healthcare sector, and he appears regularly as a guest commentator on financial television outlets such as Bloomberg, BNN, CNN and CNBC. Mr. Brozak is an outspoken advocate for the absolute need for changes in how we research and finance our healthcare system. He retired as a Lieutenant Colonel from the US Marine Corps and served on The Navy and Marine Corps Retiree Council for the Secretary of the Navy where he focused on healthcare and other retiree issues. Mr. Brozak received both his BA and MBA from Columbia University.

Steven Young, President & COO, Addario Lung Cancer Medical Institute

Steven W. Young serves as the President & Chief Operating Officer of the Addario Lung Cancer Medical Institute, a patient-founded/-focused non-profit research consortium directly linking more than 21 academic and community centers via shared infrastructures (biorepository, data system) and centrally managed intramural translational projects in the United States, France, Italy and Spain. After transitioning from the clinical research information technology industry, Mr. Young had played a central role in the development and early evolution of the Multiple Myeloma Research Consortium as its Executive Director from 2003 through 2008. Earlier still, he served as Director of the National Institutes of Health-funded General Clinical Research Center at Mount Sinai School of Medicine and the Pediatric Clinical Research Center at Cornell University College of Medicine, both in New York City.

Shakti Narayan, Sr. Director, Transactions, Johnson & Johnson Innovation, Boston

Previously, Shakti led Business Development at Nodality, a VC-backed personalized medicine biotechnology company developing predictive clinical diagnostics and more efficient drug development approaches in cancer and autoimmune disease. Prior to that, he held positions in Business Development at Genentech, and he practiced life sciences transactional law at Wilson Sonsini Goodrich & Rosati.

During his career, Shakti has led and closed multiple life sciences transactions, leveraging his interests and training in science, business and IP/contract law. Shakti earned his BA degree in Biology from Grinnell College. He earned a PhD in Cellular & Molecular Biology at the University of Wisconsin-Madison & the Salk Institute, and he was a post-doctoral scientist at Stanford University. His legal studies were completed at the University of California- Berkeley Law School, where he earned a JD.

Stuart Barich, Managing Director, Raymond James Financial, Inc.

Stuart has been with Oppenheimer since September 2005 as a Managing Director focusing on Life Sciences. He has participated in the successful completion of over 250 transactions during his career, covering a broad spectrum of equity and mergers and acquisitions. Prior to joining Oppenheimer, Stuart spent five years at Leerink Swann completing numerous transactions for Biotechnology and Specialty Pharmaceutical companies. He previously directed the healthcare banking efforts at Oscar Gruss & Son and Auerbach, after beginning his career as a Corporate Finance Associate with Paine Webber. Stuart graduated with a BS in Electrical Engineering from the University of Rochester and an MBA with honors from Columbia Business School.



WELCOM

ESPEAKERS

Speakers

3rd ANNUAL



t back :: next u

Thomas H. Tulip, President and Chief Business Officer, Navidea Biopharmaceuticals

Dr. Thomas H. Tulip is Executive Vice President and Chief Business Officer at Navidea where he also served as President from May 2013 through December 2014. Dr. Tulip has held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb (BMS) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. Most recently, as President, Alseres Molecular Imaging, Dr. Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS prior to Alseres, he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise, successfully built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at Lantheus/BMS. Dr. Tulip earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from the Northwestern University. He was a visiting scholar at Osaka University and served as adjunct professor at Northeastern University. Tulip serves on the Board of Directors of the Medical Imaging Technology Association (MITA) and leads its PET Working Group in the Molecular Imaging Section. He was recently Chairperson of the Institute for Molecular Technologies (IMT] and held numerous leadership positions there. He served on the Board of the Academy of Molecular Imaging including as its Treasurer. Tulip was Chairperson for the Society of Nuclear Medicine (SNM) Corporate Advisory Board and has been active in a number of Council on Radionuclides and Radiopharmaceuticals (CORAR) committees, now serving on its Board of Directors.

Todd Foley, Managing Director, MPM Capital

Todd Foley joined MPM’s Boston office in 1999 and was promoted to partner in 2007. He has focused primarily on biotech investments and currently serves on the boards of Chiasma, Iconic, OSS, Rhythm, Selexys and Valeritas. Todd also manages MPM’s strategic investment relationship with Novartis, which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to thirteen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.



WELCOM

ESPEAKERS

3rd ANNUAL



Actinium Pharmaceuticals, Inc. www.actiniumpharmaceuticals.com

CONTACT Kaushik J. Dave PhD, CEO

ADDRESS 546 Fifth Avenue 14th FloorNew York NY 10036

TELEPHONE +1 646 840-5442

EMAIL [email protected]

YEAR FOUNDED2000

COMPANY PROFILE

Actinium Pharmaceuticals, Inc. is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

PRODUCT PIPELINE

Iomab-B : Phase III readyIomab-B (131I-BC8), is being developed for combination with non-myeloablative conditioning (NMA) prior to hematopoietic stem cell transplantation (HSCT; also called bone marrow transplant or BMT) in older relapsed/refractory AML patients.

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

Actimab-A : Phase I/IIActimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based on Actinium’s alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from leading experts at the prestigious and high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at world-class cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and now the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects interim Phase I/II clinical trial results in December 2014. Actimab candidates are in early development for other cancers.

OPPORTUNITIES

Iomab-B Iomab-B will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission could include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: expanding the

t back :: next u

Continued...



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Actinium Pharmaceuticals, Inc. www.actiniumpharma.com

CONTACT Kaushik J. Dave PhD, CEO

ADDRESS 546 Fifth Avenue 14th FloorNew York NY 10036

TELEPHONE +1 646 840-5442


YEAR FOUNDED2000

pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Actimab-AActimab-A, based on the Company’s alpha emitter (Actinium-225) technology is a promising drug candidate currently being developed as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients ages 60 years and older.

Actimab-A is currently in an ongoing Phase I/II trial, following three previous successful trials, including two with Bismab-A, a first-generation construct.

The target population includes secondary AML, a common form of AML in the U.S., defined as AML that develops following exposure to cytotoxic agents or as a subsequent event in another hematologic disorder, usually MDS. According to the American Cancer Society, there is an annual incidence of 12,000 new cases of MDS in the U.S. Between 30% and 50% of these new cases go on to develop AML, or approximately 3,600-6,000 secondary AML patients in the U.S.

Elderly, high risk patients ordinarily have a life expectancy of 5 or fewer months if treated with standard chemotherapy, though only about a third of them do receive treatment because of toxicity. The other two-thirds receive best supportive care, with 2 months survival, according to Oran and Weisdorf (Haematologica 2012; 1916-24).

MANAGEMENT

Sandesh Seth, MS Executive ChairmanKaushik Dave, PhD, CEODragan Cicic, MD, CMODavid Gould, MD, SVP, BD

...continued



WELCOM

ESPEAKERS

3rd ANNUAL



Advaxis www.advaxis.com

t back :: next u

CONTACTInvestor Relations/ Business Development Gregory T. Mayes Chief Operating Officer

ADDRESS 305 College Rd East Princeton, NJ 08540

TELEPHONE +1 609 452 9813


YEAR FOUNDED2002

COMPANY PROFILE

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis’ immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

ADXS-HPV, Advaxis’ lead immunotherapy in in Phase 1/2 development for the treatment of HPV-associated cancers, including cervical cancer, head and neck cancer, and anal cancer. Advaxis has granted exclusive licenses for the development and commercialization of ADXS-HPV in Asia and India.

ADXS-cHER2 is an immunotherapy for the treatment of HER2 overexpressing cancers that is in preclinical development for breast cancer and Phase 1 development for canine osteosarcoma.

Advaxis has created more than 15 distinct immunotherapies based on its platform, either directly or through strategic collaborations with recognized cancer centers of excellence such as: the University of Pennsylvania, Brown University, the Georgia Regents University Cancer Center, the Icahn School of Medicine at Mount Sinai, and others.

MANAGEMENT

Daniel J. O’Connor, President and Chief Executive OfficerDr Robert Petit, Executive Vice President and Chief Scientific OfficerGregory T. Mayes, Executive Vice President and Chief Operating Officer



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Argos Therepeutics, Inc. www.argostherapeutics.com

CONTACTJeff Abbey President & CEO

ADDRESS 4233 Technology Dr.Durham, NC 27704 USA TELEPHONE+1 919 287 6300


YEAR FOUNDED1999

COMPANY PROFILE

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos’ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients.

PRODUCT PIPLINE

Arcelis® : N/A - Technology Platform Arcelis is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient’s disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient’s own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient’s disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient’s plasma and administered via intradermal injection.

AGS-003 : Phase 3 AGS-003 is an investigational, fully personalized immunotherapy for cancer comprised of autologous tumor RNA-loaded dendritic cells. AGS-003 is currently being evaluated in the ADAPT trial for the treatment of metastatic renal cell carcinoma (mRCC). This is a randomized, international Phase III trial comparing standard targeted therapy plus AGS-003 to standard therapy alone. The trial is expected to complete accrual by the end of Q1 2015.

In it’s phase 2 combination trial, treatment with AGS-003 in combination with sunitinib in unfavorable risk mRCC patients resulted in median progression free survival of 11.2 months and median overall survival of 30.2 months. In recently published findings from the International mRCC Database Consortium, unfavorable risk mRCC patients had an expected median progression free survival of 5.7 months and median overall survival of 14.7 months. For the patients with intermediate risk (1-2 risk factors) mRCC in the Company’s Phase II study, treatment with AGS-003 in combination with sunitinib resulted in median overall survival of 57.1 months or nearly 5 years.

AGS-004 : Phase 2 Argos’ second Arcelis-based product candidate, AGS-004, is currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. The AGS-004 development program is being entirely funded by a $40M NIH contract.

MANAGEMENT

Argos’ internal management team and Board of Directors have extensive experience with both the science and business of

biotechnology, ranging from preclinical to clinical development, product launch and marketing, to manufacturing commercial

products.



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTJill Horowitz, PhD CEO and Head of Business

ADDRESS 75 Sheldrake Place New Rochelle, NY 10804 USA

TELEPHONE +1 914 689 5804


YEAR FOUNDED2008

FINANCIAL SUMMARY

Private

COMPANY PROFILE

BBS Nanotech is an early-stage, EU-based biotech company of 16 employees seeking to build upon its POC animal data for cancer treatment and diagnosis. BBS has a proprietary portfolio of nanoencapsulated cancer drugs and diagnostics that are safe, easy to manufacture and biocompatible. BBS management and scientific advisory board are internationally recognized executives and oncologists with >25 years of large pharma R&D experience.

PRODUCT PIPELINE

DDS1 : pre-clinical POC Nanoencapsulated doxorubicin

DDS2 : pre-clinical POC Nanoencapsulated epirubicin

CA1 : pre-clinical POC Nanoencapsulated PET agent

DDS3 : pre-clinical POC Nanoencapulated paclitaxel

DDS4 : pre-clinical POC Nanoencapsulated docetaxel

OPPORTUNITIES

DDS1: Development rights for DDS1

DDS2 : Development rights for DDS2

CA1 : Development rights for CA1



MANAGEMENT

Jill Horowitz, PhD, CEO and Head of BusinessJanos Borbely, PhD, CSO and FounderIstvan Alpek, MBA, Director Primus CapitalFranz Krejs, PhD, Director Primus CapitalFabian Kiessling, MD, Head of Imaging University Hopital Aachen, Scientific Advisory BoardMaxine Jochelson, MD, Director of Radiology Memorial Sloan Kettering, Scientific Advisory BoardZsolt Horvath, MD, Director of Institute of Oncology University of Debrecen, Scientific Advisory BoardLeslie Botnick, MD, Chief Medical Officer and Founder Vantage Oncology, Scientific Advisory Board

BBS Nanotechnology bbsnanotech.com

t back :: next u

E M E R G I N G



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Berg LLC www.berghealth.com

CONTACTSNiven R. Narain CEO

Media & Investor Relations Christine Jackman Ogilvy Public Relations

ADDRESS Berg LLC500 Old Connecticut Path Framingham MA

Berg LLC 1845 Elm Hill Pike Nashville TN TELEPHONEChristine Jackman +1 212 880 5379

YEAR FOUNDED2006

COMPANY PROFILE

Therapeutics Berg focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg is well positioned for rapid commercialization of its intellectual capital.

Diagnostics Berg Diagnostics, a business division of Berg, is at the forefront of realizing the promise of Personalized Medicine. The advent of high-throughput molecular technologies such as metabolomics, lipidomics and proteomics that carries beyond the realm of genomics leads to fundamental understanding of disease progression and response to therapy. Berg’s multi-model panels of molecular biomarkers are to deliver unprecedented accuracy in clinical testing in indications such as cancer, CNS, diabetes, and cardiovascular disease.

Healthcare Analytics Berg’s application of Artificial Intelligence in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. Berg Interrogative Biology™ integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform provides the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary, and governments with a data ecosystem for financial modeling of healthcare needs of the population.

MANAGEMENT

Niven R. Narain, President, Co-founder of Berg & Chief Technology OfficerTere Calcines, Executive Vice President & Chief Operating OfficerRangaprasad Sarangarajan, Senior Vice President & Chief Scientific OfficerSlava Akmaev, Senior Vice President of Berg & Chief Analytics Officer of Berg Analytics Division



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



BerGenBio AS www.bergenbio.com

CONTACT Mr Richard Godfrey Chief Executive Officer

ADDRESS BerGenBio AS Jonas Lies vei 91 5009, Bergen, Norway

TELEPHONE +47 535 01 564

EMAIL [email protected] [email protected]

YEAR FOUNDED2008

COMPANY PROFILE

BerGenBio is a clinical stage biopharmaceutical company focused on developing innovative drugs for aggressive, drug resistant cancers.

The Company is a world leader in understanding epithelial-mesenchymal transition (EMT) biology, which is widely recognised as a key pathway in acquired cancer drug-resistance and metastasis. Building on this original biological insight BerGenBio is developing a promising pipeline of novel EMT inhibitors.

BerGenBio intends to develop its product candidates to proof of concept stage; further clinical development and subsequently commercialisation will be through strategic alliances and partnerships with experienced global bio-pharma oncology businesses.

PRODUCT PIPELINE

BGB324: Phase 1b / 2aHighly selective, orally bio-available small molecule inhibitor of AXL. Multiple Phase Ib clinical trials are on going and selected Phase II trials planned for unique clinical opportunities.

BGB001 : Pre clinical IND enabling BGB001 – is three monoclonal antibody programs against AXL, in late stage preclinical development: one program has already been licensed to a specialist biopharma company for forward development and commercialisation.

BGB002 : Preclinical Candidate Selection This is a small molecule development program against a novel EMT target, it is in late stage lead optimisation phase. Substantial preclinical data suggests multiple clinical positions, including very aggressive triple negative breast cancer and other drug resistant cancers that are difficult to treat.

MANAGEMENT

Mr Richard Godfrey, Chief Executive Officer Prof. James Lorens, Chief Scientific Officer Dr Murray Yule PhD, Chief Medical Officer Mrs Marit Wick, Chief Financial Officer Dr David Micklem, Director of Technology and Discovery Dr Sergej Kiprijanov, Director of Preclinical & Biologics Dr Khatereh Ahmadi, Director of Business Development



WELCOM

ESPEAKERS

3rd ANNUAL



CASI Pharmaceuticals, Inc. www.casipharmaceuticals.com

CONTACTDr Ken K. Ren Director and Chief Executive Officer

ADDRESS USA 9620 Medical Center DriveSuite 300Rockville, MD 20850

China Hanhai Culture PlazaSuite 716Building 28-1 Xiang Jun Bei LiChaoyang District Beijing 100025

TELEPHONE USA +1 240 864 2600 Investor Relations: +1 240 864-2643

China +86-10-6508-6067


YEAR FOUNDED2012

FINANCIAL SUMMARY

Strong cash position, backed by successful VC’s and smart money with low burning rate, having $11.8M cash by Sept 30, 2014 reporting.

COMPANY PROFILE

CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China. CASI’s product pipeline includes exclusive rights to ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vinCRIStine sulfate LIPOSOME injection) and Captisol-EnabledTM (propylene glycol-free) melphalan (CE melphalan) for greater China (including Taiwan, Hong Kong and Macau). CASI’s development pipeline also includes its proprietary drug candidate ENMD-2076, a selective angiogenic kinase inhibitor currently in multiple Phase 2 oncology studies, and 2ME2 (2-methoxyestradial) currently under reformulation development. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

PRODUCT PIPELINE

ENMD-2076 A Candidate for Solid Tumors currently in multiple phase 2 trials in the US and/or Canada : phase 2 clinical trials An orally active, small molecule, multi-targetedkinase inhibitor with selected inhibition of Aurora A, VEGFR, FGFR, and GF, and a Mechanism of Action against angiogenesis, proliferation and the cell cycle. • Pre-clinical studies demonstrated strong anti-tumor activities in vitro and in multiple in vivoanimal models. • Good pharmaceutical PK/PD property • Good safety profile. • Low cost and easy manufacturing • Multiple publications in international journals. • FDA orphan drug designations in HCC, ovarian cancer, multiple myeloma and AML. • Strong global IP with the first patent issued in the U.S. in 2009 and in China in 2013.

Currently in phase 2 trials in the US and/or Canada in solid tumors including:

Triple-Negative Breast Cancer (TNBC) ‒Soft Tissue Sarcoma (STS) ‒Ovarian clear cell carcinoma (OCCC) ‒Fibrolamellar Carcinoma (FLC).

2-ME2 for the Treatment of Auto-Immune Disorders : Pre-IND • An orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties • Global intellectual property • Efficacy demonstrated in animal models of autoimmune disorders including rheumatoid arthritis and multiple

sclerosis • Multiple Phase I and Phase II trials in oncology patients and Phase I in healthy subjects • Excellent safety profile • Previous clinical challenge (bio-availability in human subjects) needs to be addressed.

ZEVALIN® (ibritumomab tiuxetan) injection for greater China market : marketing registration ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. It is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (NHL). ZEVALIN® is also indicated for the treatment of patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve a partial or complete response to first-line chemotherapy.

ZEVALIN® therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN® for therapy. ZEVALIN® builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope. Please see www.zevalin.com for ZEVALIN® product and safety information.

Since ZEVALIN® is already approved in the U.S. and marketed by our licensor, we expect that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs.

t back :: next u

Continued...



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CASI Pharmaceuticals, Inc. www.casipharmaceuticals.com

Marqibo® for greater China market : marketing registration Marqibo® is a novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor. Marqibo® is approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. Please see www.marqibo.com Marqibo® product and safety information.

Since MARQIBO® is already approved in the U.S. and marketed by our licensor, we expect that gaining approval from local regulatory authorities for commercialization in greater China will require a shorter timeframe than clinical stage drugs.

Captisol-Enabled™ melphalan for greater China market : pre-marketing registration Captisol-Enabled™ melphalan is a new intravenous formulation of melphalan being investigated by our licensor in the multiple myeloma transplant setting. The formulation avoids the use of propylene glycol, which is used as a co-solvent in the current formulation of melphalan and has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. The use of Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of pre-transplant chemotherapy. CE-Melphalan is expected to be the subject of a New Drug Application, which we expect will be filed by our licensor in 2014.

We will submit our import drug registration application for CE melphalan in greater China after its approval by the FDA in the U.S.

OPPORTUNITIES

Investment Opportunity: As a U.S.-based company with deep presence in China, CASI is a gateway for U.S. investors to tap into China’s fast growing pharmaceutical market, with the assurance of a NASDAQ public company.

Market: Well-positioned to addressing significant and unprecedented market opportunities in China and worldwide.

Model: Compelling business model with important North America/China synergies and competitive advantage with efficiency and effectiveness for drug development and commercialization.

Product: A strong and growing product pipeline developed under multiple models of acquisition and internal development.

Management: An experienced, motivated leadership with track record of accomplishment in both North America and China.

Money: Strong cash position, backed by successful VC’s and smart money with low burning rate.

Value Drivers: Significant defined near-term value drivers in 2015 supporting long term growth.

MANAGEMENT

Dr Wei-Wu He, Chairman, IDG-ACCEL China Fund Venture PartnerDr Tak W. Mak, Chief Scientific Advisor, Director, Campbell Family Research Institute/Princess Margaret Hospital; University Professor, University of TorontoJames Huang, General Partner, Kleiner Perkins Caufield & Byers ChinaRajesh C. Shrotriya, MD, Chairman & CEO, Spectrum Pharmaceuticals, Inc.Dr Y. Alexander Wu, CEO, Crown Biosciences, Inc.Franklin C. Salisbury, Jr., President, National Foundation for Cancer Research

OFFICERSDr Ken K. Ren, Director and Chief Executive OfficerCynthia W. Hu, JD, Chief Operating Officer, General Counsel & SecretarySara B. Capitelli, VP, Finance, Principal Accounting Officer

...continuedCONTACTDr Ken K. Ren Director and Chief Executive Officer

ADDRESS USA 9620 Medical Center DriveSuite 300Rockville, MD 20850

China Hanhai Culture PlazaSuite 716Building 28-1 Xiang Jun Bei LiChaoyang District Beijing 100025

TELEPHONE USA +1 240 864 2600 Investor Relations: +1 240 864-2643

China +86-10-6508-6067


YEAR FOUNDED2012



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTSYoram Drucker Chairman

Itamar Shimrat CEO

YEAR FOUNDED2011

COMPANY PROFILE

Cell Source (OTCBB:CLCS) is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance to effectively treat blood cancers and nonmalignant congenital diseases, facilitate safer and more accessible bone marrow and major organ transplants, and potentially both “repair” and “replace” organs. The Company’s technology addresses the holy grail of the field of immunology: how to selectively tune immune response so that it tolerates (doesn’t reject) desirable foreign incursions (e.g. life-saving transplantations) while continuing to actively reject all other incursions (i.e. threats). This innovative capability, in addition to facilitating transplants, in preclinical studies has demonstrated the ability to directly address a number of severe medical conditions including blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia. It also has the potential to treat non-malignant indications such as sickle cell anemia and scleroderma by making safe bone marrow transplants available to a broader patient pool. Cell Source’s organ regeneration platform holds the potential to repair organs (e.g. lungs damaged by cystic fibrosis) and to grow entire organs inside the patient’s body.

MANAGEMENT

Yoram Drucker, Chairman – An Israeli entrepreneur who has led two successful cell therapy technology firms. He cofounded two NASDAQ listed cell stem therapy companies Brainstorm (currently valued at ~$60M) and Pluristem (~$200M)

Itamar Shimrat, CEO – was EVP at a leading Israeli bank, with extensive international business experience, chiefly at consulting firms including McKinsey, ranging from successful global strategy programs for Citibank, Barclays and American Express to major profitability hikes at El Al Israel Airlines and Federated Department Stores

Cell Source Ltd www.cell-source.com

t back :: next u

E M E R G I N G



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CEL-SCI Corporation www.cel-sci.com

CONTACTMr Geert Kersten Chief Executive Officer

ADDRESS 8229 Boone Blvd. Suite 802 Vienna 22182 USA

TELEPHONE +1 703 506 9460


YEAR FOUNDED1983

FINANCIAL SUMMARY

Since inception in 1983, CEL-SCI has raised approximately $250 million. During fiscal year 2014, CEL-SCI raised net proceeds of approximately $31.5 million. As of September 30, 2014, CEL-SCI had approximately $8.5 million in cash on hand. In October 2014, the Company raised another $7 million.

COMPANY PROFILE

CEL-SCI is a Phase III cancer immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. CEL-SCI is conducting a 20 country Phase III trial of Multikine (Leukocyte Interleukin Inj.), its lead investigational new drug product, for the treatment of advanced primary head and neck cancer. These patients receive Multikine as a first treatment following diagnosis, ahead of the standard therapies, to activate an effective immune response, thereby reducing recurrence and increasing survival. CEL-SCI believes that the activation of an intact immune system has the greatest chance of success and represents by far the biggest market. A successful Phase III trial should lead to Multikine becoming the first standard of care treatment for these patients. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. Multikine is a mass produced product that attains specificity when injected near the tumor. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. Corporate partners with right to sell Multikine in major countries are: Teva Pharmaceuticals (Israel and 3 other countries), Orient Europharma (Taiwan and several Far Eastern countries).

PRODUCT PIPLINE

Multikine (Leukocyte Interleukin, Injection) : Phase III Multikine is an investigational cancer immunotherapeutic agent comprised of a mixture of cytokines (interleukins, interferons, chemokines, and colony stimulating factors) derived from the stimulation in culture of normal immune system cells. Manufacturing was fully developed and validated at a cost of about $100 million. Multikine is currently being tested in a global Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer.

Multikine (Leukocyte Interleukin, Injection) : Phase I Multikine is an investigational immunotherapeutic agent comprised of a mixture of cytokines (interleukins, interferons, chemokines, and colony stimulating factors) derived from the stimulation in culture of normal immune system cells. It is currently being tested in a Phase 1 clinical trial in San Diego at the Naval Medical Center in collaboration with the US Navy under a Cooperative Research and Development Agreement (CRADA)

Continued...



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CEL-SCI Corporation www.cel-sci.com

CONTACTMr Geert Kersten Chief Executive Officer

ADDRESS 8229 Boone Blvd. Suite 802 Vienna 22182 USA

TELEPHONE +1 703 506 9460


YEAR FOUNDED1983

for the treatment of peri-anal warts in HIV/HPV co-infected men and women.

CEL-2000 (LEAPS) : Preclinical CEL-2000 is the lead peptide developed from our LEAPS (Ligand Epitope Antigen Presentation System) platform technology being develop for the treatment of rheumatoid arthritis. LEAPS is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens.

LEAPS-H1N1-DC : Preclinical The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. It is the second potential treatment developed from our LEAPS platform technology.

OPPORTUNITIES

Multikine CEL-SCI is open to any reasonable partnership proposals that will allow for the development of Multikine into other solid tumors.

LEAPS CEL-SCI is open to partnership proposals that will accelerate the development of its LEAPS platform technology. As long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using LEAPS. The leading candidate derived from this technology is the rheumatoid arthritis treatment vaccine, CEL-2000.

MANAGEMENT

Mr Maximilian de Clara, PresidentMr Geert Kersten, Chief Executive OfficerMs Patricia Prichep, Senior Vice President of OperationsDr Eyal Talor, Chief Scientific OfficerMr John Cipriano, Senior Vice President of Regulatory AffairsDr Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology

...continued



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Enumeral Biomedical Holdings, Inc. www.enumeral.com

CONTACTSArthur H. Tinkelenberg, Ph.D. President, Chief Executive Officer, Director and Co-Founder

Derek Brand Vice President of Business Development

ADDRESS One Kendall Square Building 400 – Fourth Floor Cambridge, MA 02139


YEAR FOUNDED 2010

FINANCIAL SUMMARY

In July 2014, we raised $21.5 million through a private placement offering and began public trading on the OTC Markets (OTCQB) with the ticker ENUM.

COMPANY PROFILE

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells.

Our platform enables us to study rare immune cells from human patients at high resolution and measure drug effects in a patient-specific, disease-specific manner. Harnessing The Power of Human™, our platform provides a basis for developing best-in-class product candidates from a fundamental understanding of how immunotherapies work in each patient. Our vision then is to use this human-derived knowledge to better predict which antibody drug candidates are most likely to be effective in a targeted group of patients, with the goals of reducing side effects and accelerating the drug discovery process.

Initially, we are building a pipeline of immunomodulators that target checkpoint proteins (PD-1, OX40, Lag-3), which the body use to prevent runaway immune responses that can prove debilitating or even deadly. Our near term goals include preclinical testing for our internal pipeline programs in our human-driven platform, as well as in other preclinical models.

MANAGEMENT

John J. Rydzewski, Executive Chairman of the Board of Directors and Co-FounderArthur H. Tinkelenberg, Ph.D., President, Chief Executive Officer, Director and Co-FounderKevin Sarney, Vice President of Finance and Chief Accounting OfficerM. Isabel Chiu, Ph.D., Vice President of Translational and Clinical SciencesAnhco “Cokey” Nguyen, Ph.D., Vice President of Research and DevelopmentDerek Brand, Vice President of Business DevelopmentMatthew A. Ebert, General Counsel



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Erytech Pharma SA www.erytech.com

CONTACTSGil Beyen CEO

Dr Yann Godfrin CSO

YEAR FOUNDED2004

COMPANY PROFILE

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original treatment that targets cancer cells through “tumor starvation” while significantly reducing the side effects for patients. ERY-ASP/GRASPA® has recently announced positive Phase III data in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II clinical development in ALL in the USA.

The company is also developing other indications in solid tumors and certain orphan indications outside oncology. A Phase II study in pancreas cancer is ongoing and the company is exploring other solid tumor indications for ERY-ASP.

ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreas cancer, both in Europe and the USA, and has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA).

The company has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israel.

MANAGEMENT

Gil Beyen, CEODr Yann Godfrin, CSO



WELCOM

ESPEAKERS

3rd ANNUAL



immatics biotechnologies GmbH www.immatics.com

CONTACTDr Paul HighamManaging Director, CEO

ADDRESS Paul-Ehrlich-Str. 15 72076 Tuebingen Germany

TELEPHONE +49 7071 5397-0


YEAR FOUNDED2000

FINANCIAL SUMMARY

2004/2005: €14 mn Series A

2007: €40 mn Series B

2010: €54 mn Series C

2013/4: €34 mn Series D

Non-equity funding total: €6 mn

COMPANY PROFILE

immatics biotechnologies is an independent biopharmaceutical company dedicated to the rational development of novel active immunotherapies against cancer. immatics’ therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. immatics has currently three products – IMA901 for the therapy of renal cell cancer, IMA910 for the treatment of colon cancer and IMA950 for the treatment of glioma – under clinical investigation in international studies up to phase 3. Since its foundation in 2000, immatics has raised more than ‒ 142 million (US$ 159 million) in private equity in four financing rounds. immatics’ investors include dievini (Dietmar Hopp), Wellington Partners, MIG funds and AT Impf (Andreas and Thomas Strüngmann). The company has a headcount of appox. 85 people and is based in Tuebingen and Munich, Germany.

immatics’ proprietary technology platform XPRESIDENT® enables to identify several thousand TUMAPs each year and select the most relevant antigens suitable for a particular tumor type. XPRESIDENT® combines mass spectrometry, genomics, biochemistry and immunology to create an extremely efficient discovery engine with an unprecedented and rapid output of validated TUMAP candidates. In addition to multi-peptide immunotherapies, TUMAPs can also be used in the development of other immunotherapy approaches such as antibodies or T-cell receptors.

MANAGEMENT

Paul Higham, CEOHarpreet Singh, CSOCarsten Reinhardt, CMORainer Kramer, CBO

t back :: next u



WELCOM

ESPEAKERS

3rd ANNUAL



Immune Pharmaceuticals Inc. www.immunepharmaceuticals.com

CONTACTMr Daniel Teper CEO

ADDRESS 430 East 29th street Suite 940 New York 10016 USA

TELEPHONE +1 646 561 8010


YEAR FOUNDED2011

COMPANY PROFILE

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.

The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.

The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.

The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

MANAGEMENT

Daniel Teper, CEOGad Berdugo, Executive Vice President and CFODr Oshrat Frenkel, Vice President of Nanotherapeutics R&D

PRODUCT PIPELINE

t back :: next u



WELCOM

ESPEAKERS

3rd ANNUAL



ImmunID www.immunid.com

t back :: next u

CONTACTSBernhard Sixt, PhD Chairman and CEO

ADDRESS ImmunID 7, parvis Louis Néel BP50 38040 Grenoble France

TELEPHONE +33 0 438 785 770


YEAR FOUNDED2005

FINANCIAL SUMMARY

$5m investments, several $ millions in grants.

COMPANY PROFILE

ImmunID is a pioneer of immune molecular diagnostics aiming to set the global immune diagnostics standard. Its clinical product ImmunTraCkeR evaluates the T cell repertoire diversity at the genomic level. The company is ISO9001/ISO13485 accredited and provides testing worldwide to leading clinical centers and blue-chip pharmaceutical companies.

ImmunTraCkeR and ImmunIg are proprietary immune molecular diagnostics test analysing and quantifying immune competence. ImmunTraCkeR measures T-Cell repertoire diversity and ImmunIg measures B-Cell repertoire diversity using multi-N-plex qPCR on genomic DNA.

Current industrial customers are Roche, Sanofi-Pasteur, and confidential cooperations. Current clinical research customers in Europe, US and Asia.

MANAGEMENT

Bernhard Sixt, PhD, Chairman and CEOKurt Schmidt, Chief Financial Officer



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTSDr Marc Mansour Chief Executive Officer

Kimberly Stephens Chief Financial Officer

ADDRESS 1344 Summer Street Suite 412 Halifax, Nova Scotia, Canada B3H 0A8

TELEPHONE +1 902 492 1819


YEAR FOUNDED2000

COMPANY PROFILE

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

PRODUCT PIPELINE

The DepoVax vaccine platform : Phase II DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.

DPX-Survivac : Phase II DPX-Survivac consists of survivin-based peptide antigens formulated in the DepoVax™ adjuvanting platform. Survivin has been recognized by the National Cancer Institute (NCI) as a promising tumor-associated antigen (TAA) because of its therapeutic potential and its cancer specificity. Survivin is broadly over-expressed in solid tumors and blood cancers including ovarian, breast, colon and lung cancers, among others. Survivin plays an essential role in antagonizing apoptosis, supporting tumor-associated angiogenesis, and promoting resistance to various anti-cancer therapies. Survivin is also a prognostic factor for many cancers and it is found in high percentage of cancer patients. The DPX-Survivac vaccine is thought to work by eliciting a cytotoxic T cell immune response against cells presenting survivin peptides on HLA class I molecules. This targeted therapy attempts to use the immune system to actively search for tumor cells expressing survivin and destroy them.

DPX-0907 : Phase I DPX-0907 combines seven tumor associated antigens (TAAs) with Immunovaccine’s novel DepoVax adjuvanting delivery platform, allowing for the creation of a depot effect upon vaccination that presents the antigens and adjuvant to the immune system for a prolonged period of time. Treatment with DPX-0907 is designed to train the body’s T cells, sophisticated white blood cells that play a key role in fighting cancer, to recognize the

Immunovaccine Inc. www.imvaccine.com

t back :: next u

Continued...



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



antigens incorporated into the vaccine. In doing so, the T cells become programmed to specifically target and attack cancer cells, while leaving normal healthy cells unharmed. By incorporating multiple target antigens, DPX-0907 attempts to attack cancer cells through multiple avenues and potentially minimize the cancer cells’ demonstrated ability to edit and escape the impact of individual antigens.

DPX-RSV : Phase I DPX-RSV has received clearance from Health Canada to intiate a Phase I clinical study in healthy adults. The RSV vaccine is formulated in Immunovaccine’s proprietary DepoVax™ adjuvanting platform and is initially being developed to protect the elderly population from infection. In preclinical studies, the DepoVax-based vaccine demonstrated the ability to protect animals against RSV, a potentially severe respiratory virus that predominantly affects the elderly and infants. Immunovaccine plans to initiate the Phase I trial in the first half of 2015, with initial data expected later this year.

The Phase I study, which will be the first clinical trial of a DepoVax-based vaccine in an infectious disease indication, will evaluate the safety and immune response profile of the RSV vaccine candidate in healthy adults. The study, conducted at the Canadian Center for Vaccinology in Halifax and led by Joanne Langley, M.D., will enroll 40 healthy adults 50 to 64 years of age. The vaccine will be tested at two different vaccine dose levels and study investigators will assess the vaccine’s safety and immune response profile following one or two immunizations of each dose level. The trial is being co-funded by Immunovaccine and the Canadian Institutes of Health Research (CIHR).

RSV is a respiratory virus that infects the lungs and breathing passages and most commonly affects the elderly, infants and patients with compromised immune systems. It can be severe in some patients and is the second most commonly identified cause of viral pneumonia in older persons, next to influenza. Globally, it is estimated that 64 million cases of RSV infection occur annually, with 160,000 deaths. Importantly, there is currently no vaccine available for the prevention of RSV and the World Health Organization (WHO) has designated RSV as a high-priority target for vaccine development.

MANAGEMENT

Dr Marc Mansour, Chief Executive Officer Marc Mansour holds a Ph.D. in biology and has completed a Master of Business Administration. He is an expert in vaccinology and cancer immunotherapy. Since he joined Immunovaccine, Dr. Mansour led the clinical development of the DepoVax™ platform and the Company’s lead therapeutic cancer vaccine DPX-Survivac, soon entering randomized Phase II trials in ovarian cancer and glioblastoma. He represents the company to the investor and scientific communities. He continues to lead the internal development of vaccines based on the DepoVax™ platform, and externally with collaborators and commercial partners.

Kimberly Stephens, Chief Financial Officer Ms. Kimberly Stephens is a Chartered Accountant with more than 14 years of financial management experience across several industries. In her current position as Chief Financial Officer of Immunovaccine Inc., Ms. Stephens works effectively with the executive team and Board of Directors and is responsible for producing quarterly and annual financial statements and reporting, budgeting and cash flow projections, analysis, evaluation, and planning related to business activities, strategic alliances, and financing activities. Her past roles include Director of Finance for a Canadian subsidiary of an international company, Germanischer Lloyd, Director of Finance for SolutionInc, and Audit Manager in the Assurance and Advisory group of PricewaterhouseCoopers. Ms. Stephens is also an avid volunteer, holding positions as director and treasurer of BioNova, Nova Scotia Life Sciences Association, and most recently was appointed as chairperson of Habitat for Humanity Nova Scotia. She also volunteers with the Big Brothers Big Sisters of Greater Halifax.

...continued

Immunovaccine Inc. www.imvaccine.com

CONTACTSDr Marc Mansour Chief Executive Officer

Kimberly Stephens Chief Financial Officer

ADDRESS 1344 Summer Street Suite 412 Halifax, Nova Scotia, Canada B3H 0A8

TELEPHONE +1 902 492 1819


YEAR FOUNDED2000



WELCOM

ESPEAKERS

3rd ANNUAL



MaxCyte, Inc. www.maxcyte.com

CONTACTMadhusudan V. Peshwa, Ph.D. Executive Vice President, Cellular Therapies

ADDRESS 22 Firstfield Road, Suite 110 Gaithersburg, MD 20878

TELEPHONE +1 301 944 1700


YEAR FOUNDED1998

COMPANY PROFILE

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products.

MaxCyte is enabling six (6) mRNA Chimeric Antigen Receptor (CAR) human solid tumor and blood cancer clinical studies including those being led by Dr Carl June, et al at Univ of Penn and Dr Dario Campana. mRNA expands CAR therapies to solid tumors, and manages both B cell aplasia and cytokine storm toxicities

The MaxCyte® GT™ Scalable Transfection System, MaxCyte’s clinical cell loading platform, is fully developed, well validated, and commercialized, with an FDA Master File, NIH RAC clearance, and is in over one dozen clinical trials including ten with mRNA and gene editing of stem cells

Through its internal development efforts, MaxCyte is entering into clinical trials for a rapid manufacturing process for mRNA CAR dramatically reducing processing time and cost.

MaxCyte STX and VLX systems are being used by most of the top 20 biopharmas for small molecule drug discovery, protein development and vaccine manufacturing.

MANAGEMENT Douglas A. Doerfler, President and Chief Executive OfficerRon Holtz, M.B.A., Chief Financial OfficerMadhusudan V. Peshwa, Ph.D., Executive VP, Cellular Therapies

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Microbial Robotics www.microbialrobotics.com

CONTACTMr Jason E. Barkeloo CEO

ADDRESS Corporate Headquarters: PO Box 30085 Cincinnati, OH 45230 USA

TELEPHONE +1 513 252 2901

YEAR FOUNDED2009

E M E R G I N G

FINANCIAL SUMMARY

We are a global private Company.

Our first subsidiary was acquired in 2014 by a pubco for $xxMM.

With the next subsidiary exit that is in discussion with a pubco global chemical firm, we are cash flow positive.

COMPANY PROFILE

A global biotechnology firm, we develop synthetic biology-based BactoBots™ (bacteria) and ViruBots™ (viruses) using open platforms with layers of patented and proprietary technologies. These organism-based MicrobialBots™ produce, build, sense, and perform functions for the water, energy, chemical, and pharmaceutical industries.

An example of a proprietary layer is our consumable Genetics Rights Management (GeRM™) system. The GeRM system is an additive that locks down BactoBots and ViruBots from theft and release.

If your firm is a leader in productization or commercialization expert, talk with us. We partner with industry leaders who can lead the monetizing of our Open Platforms/Proprietary Layers biotechnologies.

PRODUCT PIPELINE

BactoBots : Generating revenues BactoBots (genetically enhanced bacteria) and ViruBots (genetically enhanced viruses) that are provided as Open Platforms.

Proprietary layers are then offered as revenue generating products and services. An example is our consumable Genetics Rights Management (GeRM) system that locks down the BactoBots and ViruBots from theft or environmental release.

Our synthetic biology-based products range from water technologies to therpeutics.

When we open a platform with proprietary layers of products and services, we place that technology in a subsidiary and seek to gain an exit with a pubco. The early exit should represent a 5-10X ROI within 36 months of its launch.

MANAGEMENT

Over 100 years of synthetic biology experience is represented in the Company.

Team members include PhD/MDs otolaryngology surgeons, pediatric oncologist, eukaryotic cell biologist, and prokaryotic microbiologists.



WELCOM

ESPEAKERS

3rd ANNUAL



Nanobiotix Corp www.nanobiotix.com

CONTACTSDr Patrick Tricoli VP Corp.Dev, CEO

Philippe Mauberna CFO

ADDRESS 210 Broadway Cambridge 01239 USA


YEAR FOUNDED2003

FINANCIAL SUMMARY

Nanobiotix has raised more than €78 million since its creation.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

COMPANY PROFILE

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

The company has a head quarter in Paris, France and a US affiliate in Cambridge MA created in September, 2014.

PRODUCT PIPLINE

NBTXR3 : Phase II/III

MANAGEMENT

Laurent Levy, CEOPhilippe Mauberna, CFOElsa Borghi, CMOBernd Muehlenweg, CBOPatrick Tricoli, VP Corporate Development, CEO Nanobiotix Corp.

t back :: next u



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTDr Thomas Tulip Executive Vice President, Chief Business Officer

ADDRESS 5600 Blazer Parkway Suite 200 Dublin, OH 43017 USA

TELEPHONE +1 614 793 7500


YEAR FOUNDED1983

COMPANY PROFILE

Navidea Biopharmaceuticals,is a biopharmaceutical company focused on Precision Medicine with the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™, NAV4694, and NAV5001, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and by the EMA in November 2014. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts.

PRODUCT PIPLINE

Lymphoseek® (technetium Tc 99m tilmanocept) injection : Approved Lymphoseek is a receptor-targeted imaging agent that was approved by the US FDA for guiding sentinel lymph node biopsy in patients with clinically node negative breast cancer, melanoma and certain oral cancers as well as for lymphatic mapping in patients with solid tumors for which this procedure is a component of intraoperative management. In these procedures, key lymph nodes adjacent to a primary tumor, that may contain tumor metastases, are identified and biopsied to determine if cancer has spread to these lymph nodes.

Manocept™ platform : Development The Manocept platform offers diagnostic and therapeutic applications predicated on the ability of the molecules to specifically target the CD206 mannose receptor expressed on macrophages and in certain disease states. Macrophages are an emerging target in many disorders including Kaposi’s sarcoma, rheumatoid arthritis, tuberculosis, infectious disease, autoimmune disease and cardiovascular inflammation. This platform acts as an engine for purpose-built molecules that may enhance diagnostic accuracy, clinical decision-making, targeted treatment and ultimately patient care, while offering the potential to utilize a breadth of modalities, including SPECT, PET and therapeutic compounds.

NAV4694 : Phase 3 NAV4694 is a PET imaging agent with Phase 3 registration studies underway for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s Disease (AD).

NAV5001 : Phase 3 NAV5001 is investigational small molecule radiopharmaceutical imaging agent being developed as an aid in the differential diagnosis of Parkinsonian syndromes, including Parkinson’s disease (PD) and other movement disorders, as well as Dementia with Lewy Bodies (DLB).

OPPORTUNITIES

NAV4694 : NAV4694 is a PET imaging agent with Phase 3 registration studies underway for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer’s Disease (AD). Navidea is looking for a development and commercialization partner.

Lymphoseek® (technetium Tc 99m tilmanocept) injection : Navidea is looking for commercialization partners in various countries Ex-US.

NAV5001 : NAV5001 is investigational small molecule radiopharmaceutical imaging agent being developed as an aid in the differential diagnosis of Parkinsonian syndromes, including Parkinson’s disease (PD) and other movement disorders, as well as Dementia with Lewy Bodies (DLB). Navidea is seeking a development and commercialization partner.

MANAGEMENT

Ricardo J. (Rick) Gonzalez, President and Chief Executive OfficerFrederick O. Cope, Ph.D., F.A.C.N., C.N.S., Senior Vice President and Chief Scientific OfficerThomas J. Klima, Senior Vice President and Chief Commercial OfficerBrent L. Larson, Executive Vice President and Chief Financial Officer, Treasurer and SecretaryWilliam J. Regan, Senior Vice President, Global Regulatory StrategyCornelia B. Reininger, M.D., Ph.D., Senior Vice President, Chief Medical OfficerMichael Tomblyn, M.D., M.S., Executive Medical DirectorThomas H. Tulip, Ph.D., Executive Vice President and Chief Business Officer

Navidea Biopharmaceuticals www.navidea.com

t back :: next u



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTDr Robert Dillman Vice President, Oncology

ADDRESS 420 Lexington Ave., Suite 350 New York 10170 USA

TELEPHONE +1 212 584 4180


YEAR FOUNDED 2006

COMPANY PROFILE

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

PRODUCT PIPLINE

NBS20 : Clinical Trial Phase 3 NeoStem has received U.S. FDA approval to commence a Phase 3 trial assessing the efficacy of its patient specific cancer immunotherapy DC/TC (irradiated autologous in vitro proliferating melanoma cell line loaded onto an autologous dendritic cell combined with granulocyte macrophage colony-stimulating factor {GM-CSF}) in patients with late stage metastatic melanoma. The study has Special Protocol Assessment (SPA) and Fast Track designation, and the therapy has been awarded Orphan Drug designation.

NBS10 : Clinical Trial Phase 2/3 NBS10, also known as AMR-001, the Company’s lead candidate in its ischemic repair program, is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack or AMI). NeoStem anticipates released of data from the PreSERVE AMI Phase 2 clinical trial on November 17, 2014 at the American Heart Association’s Scientific Sessions. This 160 patient randomized, double-blind, placebo-controlled clinical trial is evaluating NBS10 in patients with post ST segment elevation myocardial infarction (STEMI). Ischemia occurs when the supply of oxygenated blood in the body is restricted. NeoStem seeks to improve oxygen delivery to tissues through the development and formation of new blood vessels. NBS10 is designed to address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning NeoStem to capture a meaningful share of this worldwide market.

NBS03D : Clinical Trial Phase 1 In collaboration with UCSF and the laboratories of Drs. Jeffrey Bluestone and Qizhi Tang, NeoStem will sponsor and manufacture a Treg product consisting of polyclonally expanded Tregs for the planned Phase 2 trial to treat patients newly diagnosed with type 1 diabetes. The collaboration also includes research efforts to develop the next generation of Treg products for therapeutic use. Dr. Bluestone, the Study Director, and Dr. Kevan Herold, the Study Principal Investigator (Yale University), completed the Phase 1 study of autologous Tregs in type 1 diabetes and reported the Phase 1 results at the American Diabetes Association Scientific Sessions in Chicago being held on June 13-17, 2014. These results are expected to serve as the basis for the initiation of the Company’s planned Phase 2 study. – See more at: http://www.neostem.com/research-and-development/immunemodulation/t-regulatory-cell-program-3/#sthash.SUlJPSVs.dpuf

MANAGEMENT

Dr. David Mazzo, Chief Executive Officer and DirectorMr. Robert S. Vaters, Chief Financial Officer and DirectorDr. Hans Keirstead, President, NeoStem OncologyDr. Douglas Losordo, Chief Medical OfficerDr. Robert Preti, Chief Scientific OfficerMr. David Schloss, Vice President, Human ResourcesMrs. Catherine M. Vaczy, General Counsel

NeoStem, Inc. www.neostem.com

t back :: next u



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACT Dr Graham Kelly CEO, Executive Chairman

ADDRESS PO Box 2333 Westfield NSW 1635 AUSTRALIA

TELEPHONE +61 2 947 24101


YEAR FOUNDED 1994

FINANCIAL SUMMARY

Market Cap approx USD $37M

COMPANY PROFILE

Novogen is an Australian drug-development company listed on both the NASDAQ ( “ NVGN”) and Australian Securities Exchange ( “ NRT”). The Novogen Group includes the US-based CanTx Inc, a joint venture with Yale University.

Novogen has 2 drug technology paltforms: superbenzopyrans ( SBPs) and the Anti-tropomyocins ( ATMs)

SBP compounds have been designed to kill the full heterogeniety of cells within a cancer tumour, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene.

The ATM compounds target the cytoskeleton of the cancer cell and when used in conjunction with standard chemotherapy drugs such as taxanes and vina-alkaloids, result in the fatal destruction of the the cancer cell’s cytoskeleton.

PRODUCT PIPELINE

TRX-0025 : Pre-clinical An SBP drug with a high potency against Prostate cancer.The primary indication is castrate-resistant Prostate cancer.

TRX-009 : Pre-clinical An SBP drug that has a high potency against cancers of the neural crest. For brain cancers and melanoma in ADULTS, and brain cancers and Neuroblastoma in CHILDREN.

Anisina : Pre-clinical An ATM drug candidate to be used to synergie and greatly increase efficacy of the taxanes and vinca alkaloids in melanoma, prostae cancer and neuroblastoma in children.

OPPORTUNITIES

All interested shareholders and investors.

MANAGEMENT

Dr Graham Kelly, CEO, Executive Chairman Dr Andrew Heaton, Vice-President Drug Discovery, Drug Manufacture Dr David Brown, Chief Scientific Officer Ms Cristyn Humphreys, Chief Operating Officer Dr Justine Stein, ATM Program Director Dr Stephen Palmer, Degenerative Diseases Program Director Dr Kimberley Lilischkis, Clinical and regulatory Affairs Director

Novogen Limited www.novogen.com

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



Office of Therapeutics Alliances,NYU School of Medicine research.med.nyu.edu/office-therapeutics-alliances

CONTACTDr Nadim Shohdy Director, Drug Discovery Partnerships

ADDRESS NYU Langone Medical Center and School of Medicine 550 First Avenue New York, NY 10016

TELEPHONE +1 212 263 8178


COMPANY PROFILE

The NYU Office of Therapeutics Alliances (OTA) serves as the drug discovery accelerator arm of NYU. OTA is transforming the way NYU commercializes its biomedical assets by adopting a nimble, proactive and pragmatic approach. Each of OTA’s pipeline projects is being de-risked to enable better prospects for partnering with biopharma or investors for startups. We mostly operate like a virtual biotech with a network of CROs and independent, ex-pharma med chem consultants, focusing on target validation, hit finding and hit to lead work. Moreover, our flexible model allows partners (pharma, investors, disease foundations, etc) to jump in at any stage during OTA’s drug discovery efforts in a shared risk/reward model.

PRODUCT PIPELINE

MANAGEMENT Dr Nadim Shohdy, Director, Drug Discovery Partnerships

E M E R G I N G



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CONTACTS Josiah C. Hornblower CEO

Taylor H. Schreiber CSO


FINANCIAL SUMMARY

Pelican is a privately funded biotechnology company developing best-in-class T cell costimulatory antibodies for immuno-oncology.

COMPANY PROFILE

Pelican Therapeutics is a virtual, privately funded biotechnology company developing best-in-class T-cell costimulatory antibodies for immuno-oncology.

PIPELINE PRODUCT

PTX-25 / Agonistic Monoclonal Antibody : Pre-Clinical A humanized, agonistic, anti-human TNFRSF25 monoclonal antibody being developed as a T-cell costimulator for use in oncology. TNFRSF25 is differentiated from other T cell costimulators (OX40, 4-1BB. GITR, ICOS) in being highly specific to memory CD8+ T cells.

OPPORTUNITIES

Pelican is exploring early-stage partnerships with PTX-25 for development and use in early stage combination immunotherapy trials.

MANAGEMENT

Josiah C. Hornblower, CEOTaylor H. Schreiber, CSO

Pelican Therapeutics www.pelicantherapeutics.com

E M E R G I N G



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CONTACTS Peter D. Suzdak, Ph.D. Chief Executive Officer

Ted Jeong, D. Mgt. Chief Financial Officer

Rick Soni, MBA President & COO

ADDRESS 15245 Shady Grove Road, Suite 455 Rockville, MD 20850

TELEPHONE +1 240 268 5300

EMAIL [email protected] [email protected] [email protected]

YEAR FOUNDED 2001

COMPANY PROFILE

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s cancer drugs have been shown to directly target cancer cells while bypassing healthy cells, demonstrating increased efficacy and reduced toxicity. These drug candidates are effective against multiple drug resistant cancers and show they can work together with FDA approved cancer treatments to increase efficacy. The Company’s nanotechnology-based drug delivery systems have shown they can make FDA approved chemo drugs more effective.

PRODUCT PIPELINEE

SupinoxinTM (RX-5902) : Phase I Clinical Trial Supinoxin is an orally administered highly potent first-in-class anti-cancer small molecule that eliminates cancer cells through inhibition of phosphorylated p68 which isfound only in cancer cells. Studies to date have shown it to be effective in tumor progression and metastasis for melanoma, cancers of the ovary, kidney and pancreas. APhase I clinical trial with Supinoxin in cancer patients is ongoing. This trial is a multi-center study, designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors. Depending upon the number of dose groups needed to determine the MTD, Rexahn expects to complete this trial in the first half of 2015.

RX-3117: Phase I Clinical Trial RX-3117 is a Next Generation cancer cell specific cytotoxic agent that inhibits DNA and RNA synthesis and induces apoptotic cell death specifically in cancer cells by a mechanism distinct from other DNA synthesis inhibitors. Preclinical studies have shown it be effective in inhibiting the growth of solid tumors in the pancreas, lung, colon, renal and others and to be effective in gemcitabine resistant cancer cells. RX-3117 has also shown efficacy in human cancer cell lines resistant to gemcitabine, which is one of the most widely used chemotherapy drugs on the market today. An estimated 25 - 40% of cancer patients receiving gemcitabine rapidly become resistant to it. An exploratory Phase I clinical trial in cancer patients was conducted in Europe in 2012 and demonstrated that RX-3117 is orally bioavailable and no adverse events were reported over the dose range tested. Rexahn expects to complete an on-going Phase Ib clinical trial in cancer patients with solid tumors in the first half of 2015. This trial is a multi-center study, designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) and preliminary efficacy in patients with solid tumors.

Archexin®: Phase IIa Clinical Trial Archexin® is a unique anti-cancer drug candidate which inhibits the activated form of the cancer cell signaling protein phosphorylated-Akt1 which is only found in cancer cells and is involved in cancer cell growth, survival, angiogenesis, and drug resistance. Archexin has completed a Phase I clinical trial in cancer patients and was shown to be safe and well tolerated. The dose-limiting toxicity was grade three sedation. In a small Phase IIa trial in advanced pancreatic cancer patients, Archexin in combination with gemcitabine was shown to be safe and well tolerated and demonstrated a preliminary efficacy signal with a median survival of 9.1 months compared to the historical survival data of 5.65 months for standard single agent gemcitabine therapy. Rexahn initiated an additional Phase IIa clinical trial in cancer patients with metastatic renal cell carcinoma in January 2014. Rexahn expects to complete the initial safety component of this study in early 2015.

RX-21101 : PC RX-21101 is a nano-polymer anticancer drug that combines its nano-drug delivery system with docetaxel, a widely used FDA approved chemo drug. RX-21101 may bolster efficacy while lowering toxicity of FDA approved chemo drugs by specific tumor targeting and increased stability in the body. Potential indications include breast, ovarian, prostate and lung cancer.

MANAGEMENT

Peter D. Suzdak, Ph.D., Chief Executive Officer Ted Jeong, D. Mgt., Chief Financial Officer Rick Soni, MBA, President & COO

Rexahn Pharmaceuticals www.rexahn.com

E M E R G I N G



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



CONTACT Mr Les Stewart President & CEO

ADDRESS 5901 Indian School Road NE Albuquerque 87110 USA


YEAR FOUNDED 2014

FINANCIAL SUMMARY

SolaranRx is seeking private equity to scale-up manufacturing, perform regulatory testing and conduct clinical studies of our peptide radiopharmaceutical platform to demonstrate proof of concept in patients. Initial funding of $3 million is being sought for an exploratory clinical study using SRX-1177 to demonstrate receptor targeting in metastatic melanoma patients. This success will enable a subsequent Phase 1/2a clinical study to demonstrate safety and preliminary efficacy of a therapeutic dose using SRX-1177 for metastatic melanoma patients. SolaranRx estimates an additional investment of $7 to $8 million will be needed to achieve this milestone and fund company operations.

COMPANY PROFILE

SolaranRx, Inc. is an early stage company driven to develop a new class of therapies and companion imaging agents for the treatment of metastatic melanoma. Our novel peptide technology demonstrates a highly specific binding to melanoma cells enabling clinicians to predict a patient’s suitability and then provide a highly targeted delivery of a therapeutic radiopharmaceutical.

PRODUCT PIPLINE

SRX-1177 : Pre-Clinical SolaranRx’s lead product, SRX-1177, is a theranostic, combining both therapeutic and diagnostic capacities. In diagnostic use, the patient is injected with a low dose to determine if they have the targeted MC1 receptor (via SPECT/CT imaging). If this is the case, patients receive higher, therapeutic doses of the same drug, delivering targeted radiation to the melanoma tumors with minimal impact on surrounding healthy tissue. This ability to identify suitable patients quickly is important, as time is the enemy for patients with melanoma. Good candidates can be treated and others can move rapidly to other therapies.

MANAGEMENT

Mr Les Stewart, President & CEODr Mary Ortner, Chief Business OfficerDr Patricia Williams, VP, R&DDr Stuart Rose, Board Chair

SolaranRx, Inc. www.solaranrx.com

E M E R G I N G



WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTGlynn Wilson, Ph.D. Chairman & CEO

ADDRESS 1551 Eastlake Ave E Suite 100. Seattle, WA 98102. USA

TELEPHONE +1 206 504 7280


FINANCIAL SUMMARY

Capital Structure Shares Outstanding 27,000,000Public Float 15,000,000Market cap $5,000,000Stock Price $0.18

COMPANY PROFILE

TapImmune is a clinical stage immunotherapy company with a set of peptide and nucleic acid technologies for the treatment of cancer and infectious disease. The Company is based in Seattle, WA. Its technologies can broadly stimulate T-helper (CD4) and T-killer (CD8) cells and can also enhance antigen presentation. Lead programs are in HER2/neu breast cancer and in ovarian and breast cancer.

The Company has an exclusive option to license peptide antigen technologies from the Mayo Foundation for Education and Research. Proprietary antigen presentation enhancing technologies (TAP; PolyStart) are owned by TapImmune. The technologies are widely applicable to cancer and infectious disease. The Company’s development pipeline is focused on cancer.

Succesful Phase I studies have shown peptide antigens to be safe and to stimulate immune responses in the majority of patients treated. These programs are ready to move into Phase II with the first Phase II study scheduled to start in Q2, 2015.

The Company plans to take programs into and through Phase II clinical but will seek development partnerships for current clinical programs and for PolyStart.

PRODUCT PIPELINE

TPIV 100: HER2/neu Breast Cancer : Phase I Set of 4 HER2/neu Class II peptide antigens discovered in HER2/neu breast cancer patients. Applicable to ~84% HER2/neu breast cancer population.

Successful Phase I studies at Mayo Clinic, Rochester, MN, have shown antigens to be safe and to produce immune responses in all patients evaluated. Program is ready to move into Phase II. One arm of Phase II

TapImmune Inc. www.tapimmune.com

Continued...

t back :: next u



WELCOM

ESPEAKERS

t back :: next u

3rd ANNUAL



studies will include TPIV 101 which is a novel Class I antigen that is 4-5 times more effective at killing human breast cancer cells in culture than Neuvax.

We believe that the combination of Class I and Class II antigens provides the most comprehensive approach for a HER2/neu immunotherapeutic

Antigens can also be used for treatment of ovarian and colorectal cancer.

TPIV 200: Ovarian & breast cancer : Phase I/II Set of 5 Class II antigens against folate receptor alpha which is overexpressed in ~90% ovarian cancers and in ~80% triple negative breast cancers.

Completion of successful Phase I has shown that the antigens are safe and produced immune responses in 20 out of 21 evaluable patients. 16 of these patients showed a long-term response. Phase II is scheduled to start in Q2, 2015. This will be a multi-center study to evaluate the ability of TPIV 200 to prevent recurrence in triple negative breast cancer patients.

PolyStart PolyStart is a proprietary DNA expression vector with two functional domains”

1. PolyStart which has multiple, sequential, initiation sites

2. Poly Antigen Array (PAA) which encodes a variety of antigens

Peptides expressed from PolyStart are naturally processed inside cells with 4-5 more peptide being expressed than is normally possible. PolyStart can be delivered as a DNA plasmid or in a viral vector.

PolyStart is being developed as a “boost” strategy for TPIV 100/101 and TPIV 200.

Strong patent position.

OPPORTUNITIES

TPIV 100/101: HER2/neu breast cancer Partnership possibilities for TPIV either alone or in combination with other immunotherapies.

TPIV 200: Ovarian & breast cancer

Partnership possibilities for TPIV 200 either alone or in combination with other immunotherapies.

PolyStart Partnership/outlicensing possibilities in cancer and infectious disease. Incorporation of novel tumor antigens into our current programs.

MANAGEMENT

Glynn Wilson, Ph.D., Chairman & CEOBob Florkiewicz, Ph.D., Head of ResearchJohn Bonfiglio, Ph.D., MBA, Strategic AdvisorPatrick Yeramian, MD,, Consultant Medical DirectorMark Reddish, Development Advisor & Director

TapImmune Inc. www.tapimmune.com

...continuedCONTACTGlynn Wilson, Ph.D. Chairman & CEO

ADDRESS 1551 Eastlake Ave E Suite 100. Seattle, WA 98102. USA

TELEPHONE +1 206 504 7280




WELCOM

ESPEAKERS

3rd ANNUAL



CONTACTSDr Mircea Popescu President & CEO

Dr Marius Teodorescu Chairman of the Board of Directors

Dr Sunil Metkar Director, Research and Business Development

ADDRESS XEME Biopharma Inc., 7 Deer Park Drive, Suite M-1, Monmouth Junction, NJ 08852-1921

TELEPHONE +1 732 823 1291


YEAR FUNDED 2007

FINANCIAL SUMMARY

Investments to date include $7.5 MM from the parent company (TheraTest Labs Inc.) and an ongoing investment of $1.5 MM/year. XEME Biopharma’s platform technology was developed and progressed to proof of concept studies at Biomira USA (now Oncothyreon) at the cost of about $20 MM. Finally, XEME also has access to non-dilutive sources of capital (NIH SBIR/STTR mechanisms and the current clinical partnership with Cancer Treatment Centers of America).

COMPANY PROFILE

XEME Biopharma Inc. (a wholly owned subsidiary of TheraTest Labs Inc.) is a clinical stage company currently pursuing pilot Phase I and II trials of autologous therapeutic vaccines in hematologic malignancies (OncoquestTM-L and OncoquestTM-CLL). Additionally, XEME has “off-the shelf” in situ vaccination products (OncolipinTM) for intra-tumoral (IT) treatment of operable and inoperable solid tumors. XEME’s products have demonstrated safety and indicated efficacy in two previous clinical trials out of the National Cancer Institute. With an impressive Management team, strong IP as well as disruptive manufacturing and cost advantages over dendritic cell-based autologous vaccines and check-point inhibitors, we believe that XEME’s vaccine candidates have the potential to become first to market and best in class.

PRODUCT PIPELINE

Oncoquest-CLL (autologous therapeutic vaccine) : Phase Ib clinical trial.

AGGREGON with high dose rhIL-2 and totality of patient’s leukemic antigens found in a cell lysate in a synthetic multi-membrane unit structure.

Clinical indication: Chronic lymphocytic leukemia

Oncoquest-L (autologous therapeutic vaccine) : Pilot Phase II clinical trial

AGGREGON with high dose rhIL-2 and totality of patient’s lymphoma antigens found in a cell lysate in a synthetic multi-membrane unit structure.

Clinical indication: Non-Hodgkin’s follicular lymphoma

Oncoquest (autologous therapeutic vaccine) : R&D; Preparing for Phase I/II submission

AGGREGON with high dose rhIL-2 and totality of patient’s tumor antigens found in a cell lysate in a synthetic multi-membrane unit structure.

Clinical indication: Hematological malignancies (Multiple Myeloma, Acute Myeloid leukemia) and Solid tumors (e.g. lung cancer, colorectal cancer, ovarian cancer).

XEME Biopharma Inc. www.xemebiopharma.com

t back :: next u

Continued...



WELCOM

ESPEAKERS

3rd ANNUAL



t back :: next u

OPPORTUNITIES

Oncoquest + Combination therapies : Pre-clinical AGGREGON with high dose rhIL-2 and totality of patient’s tumor antigens found in a cell lysate in a synthetic multi-membrane unit structure in combination with other therapies.

Clinical indication: Hematological malignancies and Solid tumors

Oncolipin-IT (In situ vaccination; Non-autologous on-the-shelf product, Active Immunotherapy) : IND stage Synthetic multi-membrane AGGREGON with high dose rhIL-2 for intra-tumoral administration.

Clinical indication: For “in situ” intra-tumoral vaccination of patients with operable bulky or inoperable solid tumors.

MANAGEMENT

Mircea C. Popescu, M.D., Ph.D., Founder, President and CEO – a seasoned Biotechnology executive with a strong research and development background. Previously, he was President of Oncotherapeutics, Research Fellow at Wyeth Vaccines, General Manager of Biomira USA and a Scientific Founder and Executive Director of The Liposome Company of Princeton, NJ. Dr. Popescu has published extensively in peer-reviewed journals

and holds numerous U.S. patents.

Richard J. Robb, Ph.D., Founder, Vice President R&D and QC – the co-inventor of XEME’s technology platform. He manufactured the first biotechnology-derived IL-2 while working at DuPont for use in clinical trials at NCI. He has published numerous scientific articles, reviews and book chapters, was co-

author on two issued US patents and Principal Investigator on two NCI grants.

William Reilley, Director of Manufacturing – has a thorough and comprehensive experience in pharmaceutical/biopharmaceutical manufacturing, process development, scale-up, tech transfer, and sterile filling experience. Bill held Director level positions at Smith-Kline Beecham (now Glaxo

Smith-Kline), J&J, The Liposome Company, Biomira USA and Insmed.

Larry Kwak, M.D., Ph.D., Founder, Chairman Scientific Advisory Board, Clinical Research Consultant – Chairman of the Department of Lymphoma and Myeloma and Co-Director of the Center for Cancer Immunology Research at the M.D. Anderson Cancer Center. Dr. Kwak previously served as Head of the Vaccine Biology Section at the National Cancer Institute (NCI). An author of more than 160 articles, Dr. Kwak was named to the TIME100, one of the world’s 100 most

influential people by TIME magazine in 2010.

Marius Teodorescu, M.D., Ph.D., Board Chair – the founder of TheraTest laboratories Inc., a successful manufacturer and distributor of immunoassay test kits for Rheumatology. He manufactured viral vaccines, taught Immunology to medical students, graduate students and physicians. He also practised Rheumatology for 25 years. Dr. Teodorescu has more than 120 publications of original work, inventions, review

articles and books in Immunology, Rheumatology and related fields.

XEME Biopharma Inc. www.xemebiopharma.com

CONTACTSDr Mircea Popescu President & CEO

Dr Marius Teodorescu Chairman of the Board of Directors

Dr Sunil Metkar Director, Research and Business Development

ADDRESS XEME Biopharma Inc., 7 Deer Park Drive, Suite M-1, Monmouth Junction, NJ 08852-1921

TELEPHONE +1 732 823 1291


YEAR FUNDED 2007

...continued



WELCOM

ESPEAKERS

Sponsors and Supporters


3rd ANNUAL


t back :: next u

www.berlinpartner.de

First choice: Berlin Partner for Business and Technology

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.

A unique public-private partnership, Berlin Partner for Business and Technology collaborates with the Berlin State Senate and over 200 companies dedicated to promoting their city. Berlin Partner is also responsible for marketing the German capital to the world, for example with the successful “be Berlin” campaign.

Berlin Partner



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.biodeutschland.org

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

BIO Deutschland



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.biotechgate.com

Your source for life science companies and licensing information.

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems – and even more.

Biotech Gate



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.edisongroup.com

Edison is a UK-based investment intelligence firm.

It employs more than 70 equity analysts operating from offices in London, New York, Sydney, Wellington and Frankfurt that provides research coverage on more than 700 publicly traded companies, making it one of the largest dedicated small and mid-cap research providers worldwide. Healthcare is the largest industry group within Edison with 12 analysts covering some 150 biotech/medical device companies located in UK, Continental Europe, North America and Australia.

Edison



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

BostonFreeMind Group423 Brookline Ave. #124Boston, MA 02215

Washington DCFreeMind Consultants4094 Majestic lane # 269Fairfax, VA 22033

JerusalemFreeMind GroupHi - Tech CenterHebrew UniversityJerusalem 95702Israel



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy.

With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities.

Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our bases in London, Manchester, Munich, Boston, Melbourne and Sydney.

Instinctif Partners



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


http://labiotech.eu

LaBiotech.eu is the free and extensive European biotechnology news website.

Launched in September 2014, this young and dynamic media is the best way for you to keep a watch on the business and innovations of biotechnologies. Thanks to our partnerships with major european biotech events we are also your dedicated website for event summaries and agenda. You can also subscribe to our weekly newsletter to receive the latest news.

LaBiotech.eu



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.lifesciencenation.com

Life Science Nation (LSN) accelerates the business of early stage life science via a Match.com-like sourcing platform.

This platform enables executives to find firms that are a fit for their business profile. Professionals leverage LSN to generate a global target list (GTL) of qualified prospects, greatly enhancing marketing efficiency. LSN researches and curates market intelligence on two industry sectors: The first is emerging biotech and medtech companies, which by their ephemeral nature are challenging to find and track. Second, LSN tracks ten categories of early stage life science investors and identifies who is filling the void left by venture capital. LSN has developed unique methodologies for tracking and keeping up-to-date with both of these dynamic market segments.

LSN created and manages the successful Redefining Early Stage Investments (RESI) conference series, which brings together global early stage biotech and medtech companies with early stage investors. LSN has also written and published a book, The Life Science Executive’s Fundraising Manifesto as well as a weekly newsletter, Next Phase, with a readership of 15,000. Finally, LSN presents a Fundraising Boot Camp at conferences and partnering events around the globe and provides seminars on branding, messaging, outbound marketing and sales to incubators and venture development centers within the life sciences.

Life Science Nation



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


www.onenucleus.com

One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.

Vision: For One Nucleus and our members to be the top European life science and healthcare network.

Mission: We will achieve this by maximising the global competitiveness of our members.

Organisation History: Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster.

The company has over 470 organisations as members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

One Nucleus’s mission is to maximise the global competitiveness of our members. For our science and technology-based members, that means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For our business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

One Nucleus



WELCOM

ESPEAKERS

t back :: next u



3rd ANNUAL


Swiss Biotech Association www.swissbiotech.org

SwissBiotech – One Nation – One Biotech Cluster

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies.

Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries:SwissBiotech, Executive OfficeTel. +41 (0)44 455 56 78 [email protected]



WELCOM

ESPEAKERS



3rd ANNUAL


t back :: next u

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics.

We work with both public and private emerging growth companies:

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc.35 W. 35th Street, 5th Floor, New York, NY 10001-2205

Tel: 212.827.0020 Fax: 212.827.0028 Fax

Tiberend Strategic Advisors, Inc.

www.sachsforum.com

Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

The benefits of conference participation with Sachs Associates may be summarised as follows:

Multimedia ExposureSachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies,including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long establishedrelationships with other financial press organisations globally, which allow further effective distribution onbehalf of its clients.

Eminent SpeakersSachs Associates is committed to ensuring that its events continue to provide forums with the participation ofthe most eminent speakers from the public and private sectors. Through its reputation and its long-establishedlocal relationships, the Company has attracted very senior political and economic personalities as speakersat its events.

Sponsorship and Marketing Opportunities for forthcoming eventsSachs Associates has developed an extensive knowledge of the key individuals operating within the Europeanand global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at theforefront of the industry and provides a powerful tool by which to increase the position of your company in thismarket.

Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most outof attending our industry driven events.

The following sponsorship and marketing opportunities are available at future conferences:• Conference Sponsor – including workshops and social events• Exhibition stands• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities please callSilvia Kar on +44 203 463 4890.

Sachs Associates



WELCOM

ESPEAKERS

Organisers

3rd ANNUAL



www.sachsforum.comSachs Associates



WELCOM

ESPEAKERS

www.sachsforum.com

3RD

AN

NU

AL

SA

CH

S C

AN

CER

BIO

PA

RTN

ERIN

G &

IN

VES

TMEN

T FO

RU

M

27 Belsize LaneLondon NW3 5AS

Tel: +44 (0)203 463 4890Fax: +44 (0)207 691 7919

Follow us on Twitter – @SachsAssociates

We look forward to seeing you at:

8th Annual European Life Science CEO Forum & Exhibition Partnering & Investing In Biotech & Pharma Industry

03rd – 04th March 2015 • Hilton Zurich Airport Hotel www.sachsforum.com/zurich_elsceo15

Sachs Immuno-Oncology: BD&L and Investment Forum

29th May 2015 • Chicago • USA

15th Annual Biotech in Europe Forum

For Global Partnering & Investment29th – 30th September 2015 • Congress Centre Basel

www.sachsforum.com/basel15

3rd Annual Medtech & Diagnostics Innovations Summit

16th November 2015 • Düsseldorf • Germany

Review the 2014 Forum: www.sachsforum.com/mdis14

3rd annual sachs cancer bio partnering & investment forum

Documents